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Advanced stage ovarian cancer has poor prognosis and lower survival rates in 
females.  A logical alternative treatment option is intraperitoneal (i.p.) chemotherapy 
leading to a high concentration of the drug in the peritoneal cavity.  However, severe 
toxicity related issues exist with drugs that are rapidly absorbed back into the 
systemic circulation or have poor absorption rates in solid tumors. A potential 
solution to this problem is intracellular delivery of the drug after local administration.  
It has been found that more than 90% of the ovarian cancers of epithelial origin 
demonstrate an enhanced folate receptor (FR) expression that has minimal presence in 
normal tissues or organs. Chemotherapeutic agents encapsulated in FR targeted 
liposomes have shown potential for increased therapeutic efficacy and decreased 
toxicity. Since, carboplatin is widely used as a first line treatment of ovarian cancer; 
therefore, intracellular delivery of carboplatin through FR targeted liposomes could 
present a viable option for the treatment of FR overexpressing ovarian cancers.  
Thus the main focus of this thesis was to develop an folate receptor targeted 
liposomal formulation of carboplatin  and test its in vitro and in vivo efficacy in an FR 
overexpressing ovarian cancer human xenograft model.  
The optimised FR targeted (FRT) and non-targeted (NT) carboplatin 
formulation showed significantly higher drug loading when compared to different 
cisplatin liposomal formulations.  When tested in the well known FR positive cell line 
KB cells, the FRT liposomes showed significantly higher cytotoxicity when compared 
to free drug or NT liposomes (p<0.05).  This enhancement in efficacy was correlated 
with significant increase in cellular platinum-accumulation (p<0.05) and strong 
activation of ERK (extracellular signal-regulated protein kinase). 
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Following this, the optimised formulations were evaluated in FR positive 
IGROV1 ovarian cancer cells.  Carboplatin loaded FRT liposomes were 
intraperitoneally injected to SCID mice inoculated i.p. with FR overexpressing 
IGROV1 cells.  Superior survival rates (>83%) were achieved in IGROV1 tumour 
bearing mice treated with FRT liposomes, with five out of six mice surviving until 
day 60 post tumour cell inoculation.  The log-rank test indicated significant difference 
when comparing FRT liposomes to saline control, free carboplatin and NT liposomes 
treated mice (p<0.01).  Moreover, the histopathological evaluation of excised tissues 
indicated metastasis of neoplastic cells in all study groups except for FRT liposome 
treated mice that survived the study period.  Of note, FRT liposome treated mice did 
not show any potential signs of toxicity. 
In order to improve the long-term stability of the liposomes, lyophilisation of 
drug free FRT and NT liposomes was investigated. Results demonstrated that sucrose 
at sugar-to-lipid molar ratio of 5:1 was superior to glucose and trehalose as 
cryoprotectant for lyophilisation of both NT and FRT liposomes. This lyophilised 
product was stable for 1 year. Most importantly carboplatin loading into the empty 
lyophilised liposomes was significantly higher (p<0.05) than its non-lyophilised 
counterpart in NT liposomes and showed similar loading in FRT liposomes.  
Overall, this thesis was successful in developing a folate receptor targeted 
liposomal formulation of carboplatin which demonstrated significant potential for the 
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1.1 Overview of ovarian cancer  
1.1.1 Ovarian cancer and statistics 
According to National Cancer Institute (NCI), United States, ovarian cancer is 
defined as a “cancer that forms in tissues of the ovary”.  NCI has classified ovarian 
cancer broadly as two types “ovarian cancer of epithelial origin, which originates 
from the cells on the surface of the ovary” or as “malignant germ cell tumours which 
begins from the germ (egg) cells”. 
Despite several approaches to treat advanced stage ovarian cancer, it is still 
one of the leading causes of cancer related death in women [1, 2].  Each year 
approximately 200,000 cases of ovarian cancer are diagnosed worldwide, whereas 
estimated 125,000 cases lead to non-survival of the female patients [2-7].  Although 
recent reports from National Institute of Health (NIH), United States and NCI have 
indicated a declining trend of ovarian cancer among female subjects, it is still among 
the top five female cancer types in both United States and Singapore [8]. NCI’s SEER 
cancer statistics review has estimated the  lifetime risk of ovarian cancer to be about 
1.39% ; which means among all the women born today, about 1.39% may have the 
risk of developing ovarian cancer in their lifetime [9].  This indicates about 1 in every 
72 women will be diagnosed with ovarian cancer during their lifetime and it is also 
predicted that 1 in every 173 women will develop the disease at 50-70 years [9].  Out 
of these cases, less than 20% of patients diagnosed with stage IV disease had a 5 year 





1.1.2 Stages of ovarian cancer 
In the human body, cancer can spread by different routes.  Cancerous cells can 
either invade the surrounding normal tissues or can invade the lymphatic system or 
blood vascular system.  When this happens, neoplastic cells can travel to distant 
organs through lymph vessels, veins and capillaries.  Based on this and the severity of 
the disease progression, NCI has classified ovarian cancer into four different stages as 
follows [10].  
 
Stage I: In general, ovarian cancer is denoted as stage I when cancer cells are found 
in one or both ovaries and are found superficially on the surface of the ovaries.  At 
times, cancer cells could also be detected in the accumulated abdominal fluid.  As 
seen in Figure 1.1, when the cancerous growth is detected in only one of the ovary it 
is subdivided into Class IA ovarian cancer.  Presence in both ovaries are denoted as 
Class IB, whereas Class IC denotes additional presence on the capsule of the ovaries 
or in peritoneal fluid as mentioned before.   
 
 





Stage II: In stage II, cancer cells spread across the pelvis and therefore can be found 
in ovaries, fallopian tubes and uterus (stage IIA), or to the tissues within the pelvis 
(stage IIB).  However, stage IIC is more aggressive whereby neoplastic cells have 
invaded the uterus along with the fallopian tubes and cancerous growth can be found 
in the pelvis and peritoneal fluid.   
 
Stage III: It is during stage III when ovarian cancer cells start to metastasise to the 
nearby lymph modes and to tissues outside the pelvis.  This stage is subdivided into 
stage IIIA when cancer cells have spread to the surrounding tissues in pelvis and have 
also reached to the surface of the liver.  Stage IIIB indicates the condition where the 
tumour size is about 2 cm or smaller and its presence is found in the peritoneum. 
Stage IIIC denotes a condition in which the tumour size is bigger than 2 cm and has 
spread to the lymph nodes and to the abdomen.  
 
Stage IV: However, it is most aggressive in stage IV when cancer cells migrate to 
almost all major organs in the body [10].  As indicated by Figure 1.2, at this stage 
cancer cells are found in the lymph nodes, lungs, liver and even on the bones. Fluid 
accumulation may also occur in the lungs and the chest wall.  Cancer cells at times 
may also metastasise within the tissues of the liver in this stage.  This stage is also 
known as advance stage ovarian cancer [10]. 
Other than these stages, ovarian cancer, which has recurred back after treatment, is 







Figure 1.2: Stage IV: Metastasis of ovarian cancer to different organs of female body 
[Source Ref [10]] 
 
1.1.3 Screening of ovarian cancer 
There are certain risk factors which may increase the chances of having 
ovarian cancer in the life time; however, no comprehensive list is available yet [11].  
Having a family history of ovarian cancer, or taking fertility drugs or hormone 
replacement therapy may be associated as risk factors.  Additionally, obesity, old-age, 
or hereditary conditions such as non-polyposis colon cancer may induce the risk of 




Detecting ovarian cancer at an early stage is perhaps the most challenging 
aspect of the disease.  Till now, there is no standard screening test available for this 
purpose and development of a conforming procedure is still under clinical trials [13].  
However, there are diagnostic tests that may be helpful in detecting the presence of 
tumours such as;  
a. A physical examination of the pelvic to feel the presence of tumour. 
b. Trans-vaginal ultrasound of the vagina, uterus, fallopian tubes or bladder to 
detect any tumour mass. 
c. CA-125 (cancer associated antigen 125) assay that measures the level of this 
tumour marker, which is sometimes elevated in certain types of cancer 
including ovarian cancer [13].   
However, the above screening tests are not exhaustive and the risk of getting a 
false-negative or false-positive result is present.  In most cases, such as for pelvic 
examination, ovarian cancer may be detected only when the disease has reached an 
advanced stage.  Once the cancer has been detected, the staging of the disease state is 
done by biopsy or by an operation called laparotomy [13].  
 
1.1.4 Treatment regimen for ovarian cancer 
The most standard treatment regime for ovarian cancer includes surgical 
intervention, radiation therapy, chemotherapy, or a combination of either or all of 
them [14].  Initially, complete removal of the tumour mass is attempted by surgical 
procedures.  This may involve the removal of the whole affected organ or removal of 
collective organs such as uterus, single or both ovaries, one or both fallopian tubes 




External or internal radiation therapy may be given to the patient depending on 
the stage of the disease.  When X-rays or other radiations are applied from an external 
source onto the cancer cells it is known as external radiation.  Whereas, when 
radioactive substances are injected into the patient body it is termed as internal 
radiation.  For the treatment of ovarian cancer, intraperitoneal (i.p.) radiation therapy 
is commonly practiced [14].  
When drugs are used to inhibit the growth of cancerous cells, it is known as 
chemotherapy, whereas use of more than one drug for the treatment is known as 
combination chemotherapy.  In general, chemotherapy is administered intravenously, 
however, in recent times intraperitoneal chemotherapy has shown some advantages 
over this conventional route of administration.  This will be discussed in details in the 
following sections.  Currently the use of biologics to fight ovarian cancer is under 
clinical trials.  Here biological agents are injected to the patient’s body to boost her  
immune system against ovarian cancer [14].  
When epithelial ovarian cancer is detected in stage I or II, the typical treatment 
regime would include the surgical removal of the organ or organs having the tumour 
mass.  However, the treatment regime may include clinical trials of surgical 
procedures or clinical trials of radiation therapy or clinical trials of chemotherapy.  At 
times standard chemotherapy may be given to patients following surgical methods 
which are under clinical investigations [14]. 
Cytoreduction is also performed when epithelial ovarian cancer is detected at 
stage III or IV [16].  The treatment regimen following surgery depends on the size of 
the tumour mass remaining in the patient’s body.  If the remaining tumour mass is 
smaller than 1 cm, combination chemotherapy is applied.  Here the mode of 




size is bigger than 1 cm, additional treatment methods may be required such as 
clinical trial of combination chemotherapy (including intraperitoneal route) along 
with  secondary surgery to determine the presence of any remaining cancer cells.  
Unfortunately, advance stage ovarian cancer recurs back even after treatment and 
therefore it is difficult to eradicate the disease.  For the treatment of such recurrent 
ovarian epithelial cancer, combination chemotherapy is the usual treatment which 
may or may not be accompanied by surgical intervention [17].  If the patient response 
is poor, they may be put under clinical trials of surgical methods or clinical trials of 
biological therapy alone or with combination chemotherapy [14, 17].  
 
1.1.5 Intraperitoneal administration of chemotherapeutics for the treatment of 
ovarian cancer 
The standard chemotherapeutic regime for ovarian cancer of epithelial origin 
usually consists of i.v. administration of platinum (Pt) drugs such as cisplatin or 
carboplatin often in combination with paclitaxel [18].  However, inadequate drug 
concentration at the tumour site after systemic administration of the drug(s) is one of 
the major causes of treatment failure in solid tumours of peritoneal origin [19, 20].  A 
logical alternative way of treatment would be intraperitoneal (i.p.) therapy leading to a 
high concentration of the drug in the peritoneal cavity [17].  The pharmacological 
rationale behind this route of intervention for ovarian cancer treatment was 
established back in late 1970s and early 1980s [21, 22].  Scientists argued that high 
intraperitoneal concentration of Pt and taxane (such as paclitaxel) drugs and their 
longer half-life in the peritoneal cavity may result in greater exposure of the drug to 
the local tumours [22, 23].  This was evident in patients having tumour of less than 1 




concept was established by three major randomised phase III clinical trials (protocol 
SWOG-8501, GOG-14, and GOG-0172) from Gynecol Oncol Group showing 
superior survival benefit in patients with stage III ovarian cancer when treated i.p. by 
cisplatin followed by paclitaxel (i.v.) after primary surgical tumour debulking [25-27].  
Several other phase III clinical trials have also demonstrated the significant benefit of 
i.p chemotherapy over i.v. route in ovarian cancer patients [28-32].  Following this, on 
January 5, 2006, NCI announced the clinical approval of i.p. chemotherapy for the 
treatment of advanced stage ovarian cancer [33].  This combination of surgical 
debulking of ovarian cancer followed by i.p chemotherapy has shown to extend the 
overall survival for the female patients by more than one year when compared to i.v. 
route of chemotherapy [34].  However, the additional risk of infection and fever along 
with adverse side effects such as nausea, vomiting and abdominal pain due to 
presence of i.p. catheter was obvious [25].  But such symptoms were found to be 
temporary, short term, reversible and manageable [25].  Though all the randomised 
phase III clinical trials on i.p chemotherapy were based on the i.p administration of  
cisplatin, recent clinical trials by Fujiwara et al. have recommended carboplatin 
instead of cisplatin for i.p therapy [35-38].  Based on the promising results of phase I 
and phase II clinical trials, large scale randomised trial phase III on i.p administration 
of carboplatin has been recommended [39-41].  Currently several other ongoing phase 
II and phase III clinical trials are evaluating the beneficial effects of i.p. 





1.2 Carboplatin as a drug for the treatment of ovarian cancer 
1.2.1 Overview of carboplatin and its uses 
Carboplatin was derived from the parent Pt-based antineoplastic agent 
cisplatin.  The parent compound cisplatin was first mentioned by M. Peyrone in 1845 
and was known as Peyrone's salt for many decades until its use as an anticancer agent 
was deciphered by scientist Barnett Rosenberg in 1965.  Later in 1978, U.S. Food and 
Drug Administration (FDA) approved cisplatin for the treatment of testicular cancer 
and ovarian cancer under the trade name “Platinol”.  Carboplatin was later discovered 
and synthesised at the Institute of Cancer Res, London in 1980 and was approved by 
FDA as an antineoplastic agent in 1989 under the brand name of Paraplatin.  The 
chemical structures of cisplatin and carboplatin are shown in Figure 1.3. Cisplatin is 
chemically known as cis-diamminedichloroplatinum (II) whereas carboplatin is 
chemically known as cis-diammine(l,l,-cyclobutanedicarboxylato)platinum(II).  The 










Although cisplatin was the standard Pt-drug used for almost a decade, 
carboplatin was later proven to be a better analogue of the former due to its largely 
reduced side effects and better patient tolerance [43-45].  In most cases, carboplatin is 
the drug of choice over cisplatin due to its markedly reduced toxicity in the kidney 
and nervous system, yet showing similar cytotoxicity towards the neoplastic cells 
[44]. 
Carboplatin is used as a first-line or second-line chemotherapeutic intervention 
for advanced ovarian cancer of epithelial origin, small cell and non-small cell lung 
cancer.  It is less extensively used for the treatment of testicular cancer, head and neck 
cancer, Ewing's sarcoma, leukemia and brain cancer [44, 46, 47].  While numerous 
dosing schedules are available to treat advance stage ovarian cancer, the exact dose of 
carboplatin to be administered depends on the disease stage, patient response rate and 
concomitant therapy.  Dose may also be modified based on patients’ white blood cell 
count.  Generally adults are administered 400 mg/m2 i.v., once every four weeks.  
 
1.2.2 Mechanism of action of carboplatin 
Both cisplatin and carboplatin belong to the class of “alkylating-like” 
antineoplastic agents since they primarily act by damaging DNA similar to the 
alkylating agents.  They form highly reactive platinum complexes within the cell that 
inhibit DNA synthesis.  Evidence suggests that Pt-compounds form cross link 
between two adjacent guanine residues on the same strand of DNA to form intrastand 
DNA adducts, whereas in between the guanine residues on opposite DNA strands to 
form interstrand DNA adducts [48, 49].  Although carboplatin forms similar reaction 




binding kinetics and lower reactivity in vitro when compared to its parent compound 
[48].  This divergence has been attributed to the differing functional group 
attachments of the two compounds.  It was suggested that the replacement of the more 
labile chloro-ligands in the cisplatin moiety by the bidentate dicarboxylate group in 
carboplatin made it more resistant to DNA binding [50].  
Although several studies have demonstrated that the cytotoxicity of cisplatin 
or carboplatin is by inhibition of DNA synthesis due to the formation of DNA 
adducts, many recent studies have indicated the involvement of other possible 
mechanisms behind its cytotoxicity [51, 52].  In addition, subsequent studies showed 
that inhibition of DNA synthesis did not correlate with the sensitivity of different cell 
lines to the drug [53, 54].  Hence, researchers investigated other pathways of cell 
death associated with cisplatin/ carboplatin cytotoxicity.  In 1990, Eastman and co-
workers showed that these DNA crosslinks results in DNA degradation, causing an 
arrest in the G2 phase of the cell cycle and subsequent cell death by apoptosis [53, 55-
57].  Di Felice and co-workers in 1998 also reported that cisplatin and carboplatin can 
stimulate apoptosis in human retinoblastoma Y79 cells [58].  In 1999, Gong and co-
workers published an article, showing that the tumour-suppressor protein p53 can 
induce apoptosis in cisplatin-induced cytotoxicity [59].   
However, another pathway of cellular death induced by cisplatin/carboplatin 
treatment is the activation of the extracellular signal-regulated protein kinase (ERK).  
Wang et al have demonstrated the role of ERK in mediating cisplatin-induced 
apoptosis of human cervical carcinoma HeLa cells [60].  Cisplatin treatment resulted 
in dose and time-dependent activation of ERK, which is considered as a member of 
the MAPKs (Mitogen Activated Protein Kinases) family.  The study showed that 




signaling pathway such as PD98059 and U0126 could prevent apoptosis by inhibiting 
ERK pathway.  On the contrary, pre-treatment of cells with TPA, an activator of the 
ERK pathway, enhanced their sensitivity to cisplatin-induced cell death.  Similarly, 
suramin, a growth factor receptor antagonist of ERK, could inhibit cisplatin-induced 
apoptosis by suppressing ERK activation [60].  
Later, Park and co-workers extensively investigated the signaling pathways 
involved in cisplatin-induced apoptosis using a rat neuroblastoma cell line, B104 [61].  
They demonstrated that ERK plays a critical role in cisplatin-induced neuronal cell 
death as a pro-apoptotic signal. ERK was significantly activated following exposure 
to cisplatin, and inhibition of ERK pathway using the specific inhibitor blocked 
cisplatin-induced cell death [61].  Woessmann and co-workers also reported that 
cisplatin can induce cell death independent of p53 by activation of ERK in 
osteosarcoma and neuroblastoma cell lines [62].  The study showed that activation of 
the mitogen-activated protein kinases ERK1/2 first occurred in a dose-dependent 
manner starting 3–6 h from the end of cisplatin incubation and declining after 12–24 
h.  Also, incubation of the cell lines with the MEK1 inhibitors PD98059 or U0126 
after cisplatin treatment completely inhibited the cisplatin-induced activation of ERK 
[62]. 
Another recent study reported the role of p53 in ERK activation for 
carboplatin-induced apoptosis in cervical carcinoma cells [63].  In this study, the 
researchers investigated the relation between p53 and ERK in carboplatin-induced 
apoptosis in these cells.  They proposed that p53 may act as one of the upstream 
regulators of ERK activation for the induction of apoptosis in carboplatin-treated 
cervical cancer cells [63].  They also elucidated the role of cell cycle regulatory 




that DNA-damage could induce stress, which subsequently led to enhanced ERK 
activity and utilised Cdk5 as one of its downstream targets for the execution of death 
signal in MCF-7 and MDA MB-231 cells [64]. 
Apart from these major pathways as discussed above, many researchers 
suggested the involvement of several other cell-signaling pathways such as 
involvement of oxidative stress behind the cytotoxic effects of cisplatin and 
carboplatin [64-66].  
 
1.2.3 Side effects of carboplatin and the advantage of a targeted delivery system  
Despite several advantages of carboplatin over its parent compound cisplatin, 
it is often associated with several adverse effects such as myelosuppression, anemia, 
peripheral neuropathy, and stomach pain [67].  Patients seldom suffer from 
neurotoxicity or nephrotoxicity unlike cisplatin-treated patients.  At times, allergic 
reactions have been observed during or after administration especially when used as 
combination therapy [68].  However, the dose-limiting toxicity of carboplatin is bone 
marrow suppression or myelosuppresion, especially thrombocytopenia where the 
platelet count of the patients goes below 50,000/mm3 upon carboplatin treatment.  
Bone marrow toxicity is severe in patients with impaired kidney functioning and also 
when carboplatin is used in combination with other anticancer drugs which can itself 
cause myelosuppression [69].  These haematological changes are generally reversible; 
however, it may be associated with fever or other hemorrhagic complications in some 
patients [68].  Increasing exposure to carboplatin may also lead to anaemia and at 
times blood transfusion may be necessary.  Other common side effects of 
chemotherapy such as constipation, diarrhea, loss of appetite, hair loss, nausea, 




treatment.  However, patients may or may not have these symptoms, or their severity 
may also vary person to person [44].  
These adverse side effects are mostly dose-limiting toxicities which could be 
bypassed if better therapeutic efficacy is achieved by lowering drug dose.  
Administration of carboplatin via the i.p. route may be an alternative approach and 
this has been shown to have potential benefit in clinical trials as discussed in section 
1.1.5.  It has been reported that carboplatin was well tolerated upon i.p. administration 
and showed significantly less thrombocytopenia in patients [38, 40].  However, severe 
toxicity related issues still exist with drugs which are rapidly absorbed back into the 
systemic circulation from the peritoneal cavity or have poor absorption rates in solid 
tumours [20].  Unfortunately, majority of the chemotherapeutic agents including the 
platinum drugs (cisplatin and carboplatin) and paclitaxel suffer from either of these 
two pitfalls [70-75].  One approach to overcome this obstacle could be intracellular 
delivery of carboplatin after local administration.  This would not only help increase 
carboplatin accumulation in the neoplastic cells, but would also minimise the 
exposure of the normal cells to the drug.  A potential molecular target for the 
intracellular delivery of carboplatin into the ovarian cancer cells could be the folate 
receptors that are found to be overexpressed in more than 90% of the ovarian cancer 
cells.  
 
1.3 Targeted therapy for ovarian cancer 
1.3.1 Introduction to folic acid, reduced folate carriers and folate receptors 
Folic acid is an essential vitamin required by all normal cells as well as tumour 
cells for cell metabolism, DNA synthesis and repair [76]. The structure of folic acid is 
shown in Figure 1.4.  The term folate is generally used for all structurally related 
15
compounds that have same biochemical activity as the folic acid.  Folate is involved 
in the one-carbon transfer reaction occurring during DNA synthesis and replication 
[76].  It is also reported that folate may be involved in DNA repair [77].  During 
carcinogenesis, increased cellular replication requires much higher amount of folic 
acid.  Also, the inability of the malignant cells to repair DNA damage may result in an 
elevated uptake of folate during the early stages of carcinogenesis [78].   
 
Figure 1.4: Structure of folic acid 
 
Mammalian cells exhibit two major pathways for the cellular internalisation of 
the folates; namely, reduced folate carriers (RFC) and folate receptors (FR).  It is to 
be remembered that mammals are unable to synthesise the vitamins themselves and 
therefore it must be supplied through food or dietary supplements.  The vitamin folic 
acid obtained from food or dietary supplements remains biologically inactive unless it 
is converted to its reduced form methyl-tetra-hydrofolate by the enzymes in the liver 
[79].  
RFC is ubiquitous in almost all normal cells, and is the major route of entry of 
the vitamin in non-malignant cells [80].  RFC uses a bi-directional anion exchange 
mechanism to transport the reduced form of the vitamin folic acid (such as methyl-
tetra-hydrofolate) into the cytoplasm.  Since, this carrier binds and transports the 




Km prior to saturation of the carrier.  While RFC has very high affinity towards the 
transportation of pharmacologically active folates (Km 1-10 µM), it has low affinity 
for the naturally available form of the vitamin (Km 200-400 µM) or the folate-
conjugated compounds.  Most importantly, the binding capacity of RFC is several 
hundred times greater than the amount of reduced folates available in the serum [78].  
 
Table 1.1: Comparison of RFC and FR. Adapted from Keleman et al [78]. 
 
Characteristics Reduced Folate Carrier Folate Receptor α 
 
Distribution Nearly all cells Restricted 
Preferred Substrate Methyl-tetrahydrofolate 
(pharmacologically active form of 
vitamin folic acid) 
Folic acid  
(naturally obtained form of 
vitamin) 
Binding affinity for 
folic acid 
Low 
Km 200-400 µM 
High 
Kd < 1 nM 




FR are also known as folate binding proteins as they allow the binding and 
internalisation of folates or folic acid into the cells by a method called FR mediated 
endocytosis (FRME) [81].  They have restricted presence in normal cells and are 
mostly expressed during malignant transformation.  There are three isoforms of the 
FRs, namely, FRα, FRβ and FRγ. Among them, FRα and FRβ are membrane-bound 
proteins which are glycosyl phosphatidylinositol (GPI)-anchored, whereas FRγ is the 
soluble form secreted mainly by hematopoietic cells [81, 82].  Among them, FRα is 
the most widely studied FR isoform due to its overexpression in cancerous tissues.  
Therefore from this point onwards, FRα will be denoted as FR unless and until 
otherwise specified.  Since FR binds and internalises their substrate but does not play 




dissociation constant, Kd [78].  Unlike RFC, FR have high binding affinity for the 
naturally occurring folic acid and for folate-conjugated molecules.  The comparison 
between the two pathways of folate internalisation (RFC and FR) has been 
summarised in Table 1.1.  
 
1.3.2 Folate receptors as the molecular target 
Various reports have confirmed the low presence of FR in normal adult tissue 
[81].  Differential expression of FRα is found in some normal tissues such as placenta, 
bladder, kidney proximal tubules whereas FRβ expression can be found in non-
malignant cells of the placenta, spleen, thymus and neutrophils [81].  FRγ presence is 
found in hematopoietic cells as mentioned before.   
 
Table 1.2: Expression of folate receptor (FRα) in solid tumours (adapted from [83]) 
 
Solid tumours FR expressing cancers (%) 
Ovarian 90 
Uterus 90 
Brain and CNS 90 
Lungs 78 
Kidney 75 







Previous reports have confirmed that the expression FRα were significantly 
high in ovarian cancer as well as in a number of other malignant transformations [84].  
A recent report by Low et al have summarised the FRα expression in solid tumours 




shown in Table 1.2 was determined by immunohistochemical analysis of cancer 
tissues from patient samples (U.S.) using a monoclonal IgG to FRα [83].  About 90% 
of ovarian cancers are found to overexpress FRα and their elevated levels are also 
found in tumours of other epithelial lineage such as uterus, lung, colorectal, breast, 
renal cell carcinomas, and brain metastases [77].  Moreover, several investigations 
have correlated the FRα expression levels with the histological grading and response 
rate of ovarian and breast cancer [78].  This has also opened up a new avenue in 
detection of ovarian cancer by utilising FRα as a prognostic tumour marker.  Lower 
expression of FRα can also be detected in many other forms of cancer as tabulated 
[81].  Overexpression of FRβ and FRγ are detected in different types of leukemia, and 
relatively consistent expression of FRβ could be detected in lymphomas as well [78, 
81].   
This distribution of FR in different types of malignant cells and its limited 
presence in normal tissues renders it as a potential molecular target for the treatment 
of cancer [85].  In addition, the inability of reduced-folate carrier to bind and transport 
folate conjugates into normal cells significantly contributes to the low toxicity of the 
FR-targeted therapeutics [86].  Moreover, the functional FRs which can be detected 
on the normal tissues are primarily localised to the apical surfaces of polarised 
epithelia, whereby they become inaccessible to parenterally administered FR-targeted 
therapeutics [87].  However, since kidney and to some extent the placenta expresses 
FRs, these could be the potential sites for any therapy-related toxicity.  Thus far, 
several preclinical and phase I clinical studies on folate-targeted imaging agents, 
folate-targeted immunotherapeutic drug and folate-targeted chemotherapeutic drugs 





1.3.3 Folate receptor targeted monoclonal antibody 
To take advantage of FRα as a molecular target in ovarian cancer, several 
attempts have been made to generate monoclonal anti-human FRantibodies.  
Previously developed antibody MOv18 of murine origin has shown therapeutic 
efficacy in ovarian cancer patients with minor human anti-mouse antibody response 
[88].  This is a kind of allergic reaction which the patient experiences when treated 
with antibodies of mouse origin.  Another murine antibody LK26 against FRα was 
evaluated in an ovarian cancer xenograft model; however, the antibody lost its affinity 
toward the receptor upon humanisation [89].  Recently, an improved humanised form 
of LK26, known as farletuzumab, was developed [90]. It is a humanised monoclonal 
antibody (MORAb-003) with high binding affinity towards FRα.  
Several pre-clinical and clinical studies have indicated the therapeutic efficacy 
and low toxicity of farletuzumab in ovarian cancer patients [90].  In vitro studies on 
FR positive ovarian cancer cells have demonstrated superior growth inhibitory effect. 
Immunohistochemical studies with ovarian cancer tissues of human and primate 
origin showed minimal cross reactivity when compared to normal tissues [90].  A 
recently completed phase I clinical trial has also reported favourable toxicity profile 
of the antibody. In this dose escalation study, farletuzumab was administered at a dose 
of 12.5 to 400 mg/m2 to determine the maximum tolerated dose [91].  Results 
indicated that farletuzumab was generally well tolerated and safe for the management 
of pre-treated epithelial ovarian cancer patients.  No dose-limiting toxicity was 
observed up to a dose of 400 mg/m2 in a week when administered as an i.v infusion.  
Fatigue (64%), drug hypersensitivity (60%), diarrhea (32%) and nausea (28%) were 




A recent phase II clinical trial has indicated modest activity of farletuzumab as 
a single agent.  When administered in combination with carboplatin and taxane in 
platinum-sensitive or recurrent ovarian cancer patients, farletuzumab showed 
prolongation of the remission period when compared to control groups.  An ongoing 
randomised, double-blind phase III clinical trial is currently assessing the therapeutic 
benefit of administering farletuzumab in combination with carboplatin and taxane in 
patients with platinum-sensitive ovarian cancer in first relapse [92].  Another phase II 
clinical trial is currently evaluating its benefit in combination with paclitaxel in 
platinum-resistant ovarian cancer.  Several other ongoing phase I and phase II clinical 
trials are also evaluating its potential as a single agent for the treatment of lung cancer 
or for the treatment of ovarian cancer which are non-responsive to standard treatment 
methods [92, 93].  Benefits of farletuzumab therapy either as a single agent or in 
combination with other Pt or taxane drugs will be unleashed from these ongoing 
clinical trials.  
 
1.3.4 Folate receptor targeted drug conjugates 
Another alternate method of tumour targeting through FR is by the synthesis of 
folate-conjugated drug molecules.  To date, a few small molecular chemotherapeutic 
agents such as taxols and carboplatin have been conjugated with folic acid via a 
cleavable linker for the purpose of FR targeting of cancers [94, 95].  The pathway of 
entry of folate-conjugated drug molecules into the cells is similar to the internalisation 
of the vitamin folic acid [96].  Figure 1.5 illustrates the internalisation of a folate-






Figure 1.5: A schematic diagram of folate receptor mediated endocytosis of folate-
drug conjugate [From Ref [97]]. 
 
It is proposed that endocytosis begins with the grouping of FR in small 
membrane invaginations called “caveolae” and then the membrane closes to 
internalise the receptor–folate complex.  Folate is dissociated from the membrane due 
to an acid gradient caused by an increased pH of the internal compartment.  The 
unused or rather unoccupied receptors are exposed to the cell membrane for the new 
cycle of endocytosis [98].  Although this theory of “caveolae” has been debated and 
various other mechanisms of endocytosis have been proposed, it remains the most 
acceptable method of internalisation by FR [78].  It is to be noted that due to lower 
binding affinity of RFC towards folic acid conjugates, only negligible transport of 
such molecules can occur in normal cells.  
Though the concept of such folate-conjugated drug molecule seems to be 




therapeutic efficacy.  It was found that taxol-folic acid drug conjugate did not show 
any improved therapeutic efficacy over the free taxol when tested in a murine FR 
positive M109 xenograft model growing i.p. in mice.  Its failure was primarily 
attributed to the lower water solubility of the drug conjugate which prevented the 
administration of a higher dose of the drug-conjugate.  Moreover, the success of such 
drug-conjugated systems also relied upon the rate of hydrolysis of the drug-
conjugated linker which mediates the release of the free drug inside the cell.  Aronov 
et al attempted to prepare different long-circulating PEGylated carboplatin analogues 
which were conjugated to folic acid for improved targeting [95].  However, the in 
vitro cellular studies demonstrated a lower cytotoxicity of the folic-acid-conjugated-
drug analogues when compared to free carboplatin and PEGylated carboplatin 
analogues.  Their findings concluded that the folate-conjugated drug analogue may 
have been inactivated or blocked during the FRME process and may not have reached 
the cellular compartments effectively [95].  Another major limitation of the folate 
drug conjugates encountered is the low drug loading of such systems.  Since the FR 
have very high affinity for the folate-conjugated drug molecules, even very low 
amount of such drug conjugates may saturate the accessible receptors [86].  Even 
though almost 107 FR are present on a single cell, it may not be adequate for the 
delivery of anticancer drugs that have an IC50 value of more than 10-8 M [85, 99].  
Taken together, these factors indicate the need of drug delivery systems which could 
deliver the optimal drug dose within the tumour cells via FR mediated drug delivery.   
 
1.3.5 Nano-sized drug carriers targeting the folate receptors 
For the past few decades, nano-sized drug carriers (10 ~ 400 nm) have 




several advantages over conventional drugs or drug conjugates such as improving the 
poor aqueous solubility of drugs or drug conjugates and prolonging the circulation 
lifetime.  Most importantly, these carriers have the advantage of carrying a larger drug 
loading in vivo when compared to ligand-drug conjugates [100].  To date, different 
types of nano-carriers such as liposomes, micelles, polymeric nanoparticles, and 
dendrimers have been employed for FR targeted drug delivery (Figure 1.6).  
 
Figure 1.6: Commonly used nano-carriers for anti-cancer drug delivery [From Ref 
[101]] 
 
FR targeted nanoparticles have not only been utilised for cancer therapy, but have 
also been utilised for the purpose of diagnosis of cancer.  Research groups have 
developed FR targeted theranostic agents with mesoporous silica nanoparticles co-
loaded with camptothecin [102].  FR targeted micelles encapsulating cadmium–zinc 
have also been utilised for in vivo luminescence imaging in mice with xenografted 
tumours [103].  Biodegradable polymeric micelles prepared by self-assembling of di-
block copolymer of poly(D,L-lactic-co-glycolic acid) (PLGA) and poly(ethylene 




tumours. (Figure 1.7).  These FR targeted micelles showed significant tumour 
regression in mice xenografted with FR positive tumour cells [104].  
 
 
Figure 1.7: Self assembled doxorubicin micelle targeting the folate receptors [From 
Ref [104]. 
 
Several other polymeric blocks have been utilised recently to encapsulate 
doxorubicin in the FR targeted scaffold for the treatment of breast and ovarian cancers 
[105, 106].  Besides doxorubicin, researchers have also encapsulated cisplatin in 
micelles fabricated from folate-conjugated PEG grafted α,β-poly-(N-aminoacidyl) 
aspartamide.  However, the folate-conjugated micelles did not show any improved 
tumour regression than the free drug though it showed minimal toxicity in mice [107].  
Table 1.3 lists examples of different types of nano-sized carriers functionalised with 
folate ligand and encapsulating different anticancer drugs or diagnostic agents for 






Table 1.3: Examples of different types of folate functionalised nano-sized carriers for 
























Breast cancer In vivo fluorescence 
imaging 
Camptothecin  [102] 
Dendrimers Oral cancer 
(KB cells) 

















---- Doxorubicin [104] 
Polymeric 
micelles 
Breast cancer ---- Doxorubicin [105] 
Polymeric 
micelles 
Ovarian cancer ---- Doxorubicin [106] 
Lipid 
nanoparticle 









Since FR targeted nano-sized carriers are still under laboratory investigation, 
further comments on the success of such systems can only be made after sufficient 
preclinical and clinical evaluations have been performed.  However, Low and co-
workers have pointed out the limitation of such systems [99].  Since polymeric 
micelles, dendrimers or nanoparticles mostly carry their drug load on their surfaces, 




period of time for efficient targeting against the solid tumor [99].  They also require 
sufficient modifications to ensure good water solubility and folate presentations over 
their exposed surfaces [99].  All these problems are mostly obviated by liposomal 
drug delivery systems which carry their drug load within their aqueous compartments 
or hydrophobic bilayers, and are further modified with PEG lipids for longer 
circulation lifetime.  A detailed discussion on liposomes as a drug delivery system and 
its suitability for FR targeting follows.  
 
1.4 Liposomes as a drug delivery system 
1.4.1 Overview on liposomes 
Liposomes are vesicular concentric bilayered structures, which are generally 
biocompatible, biodegradable, non-toxic and non-immunogenic [112].  Liposomes 
can be composed of natural constituents such as phospholipids, cholesterol, 
sphingolipids, non-toxic surfactants, glycolipids and long chain fatty acids.  
Liposomes have the unique ability to entrap both hydrophilic and hydrophobic drugs 
in their aqueous core and lipid bilayers, respectively (Figure 1.8).  Liposomes were 
first described as phospholipid spherules by the British hematologist Dr Alec D 
Bangham in 1961 [113].  Later in 1968, Seesa and Weissman coined the term 
“liposome” and described liposome as a model system for the study of biological 




Figure 1.8: Basic structure of a liposome [Source: wikipedia] 
 
In 1974, Gregoriadis proposed liposomes as a potential carrier for 
chemotherapeutic drug [116].  Since then,  liposomal drug delivery system (DDS) was 
used to improve the therapeutic efficacy and pharmacological properties of many 
anticancer drugs [100].  Among all the nano-sized drug carrier systems present, the 
success of this DDS is evident by the number of liposomal products available in the 
market or under advanced stages of preclinical and clinical trials.  Table 1.4 is a list of 
the approved liposomal anticancer drugs.  The list also cites examples of anticancer 
drugs formulated as liposomes which are currently under clinical trials for different 






Table 1.4: Liposomal anticancer drugs approved for clinical use or under clinical 








Doxorubicin DoxilTM, CaelyxTM Kaposi sarcoma in AIDS Approved 
Myocet®, Evact® Refractory ovarian cancer, 




DaunoxomeTM Kaposi sarcoma in AIDS Approved 
Annamycin Liposomal-
Annamycin® 
Doxorubicin resistant tumours Approved 
Cytarabine Depocyt Lymphomatous meningitis Approved 
(intrathecal 
application) 
Vincristine Marquibo® Non-Hodgkin’s lymphoma, 
Acute lymphoblastic leukemia 
Phase II/III 
Lurtotecan NX211 Ovarian cancer, Phase II 
Advanced solid tumours Phase I 
OSI-211 Ovarian cancer , head and 
neck cancer 
Phase II 
Oxaliplatin Aroplatin B-cell lymphoma Phase I 
(completed) 
Colourectal cancer Phase II 
Cisplatin SPI-077 Head and neck cancer, lung 
cancer 
Phase I/II 
LipoplatinTM Several cancer types Phase II/III 
Vinorelbine INX-0125 Non-Hodgkin's lymphoma Phase I 
All-Trans-
Retinoic Acid 
Atragen® Acute promyelocytic 
leukaemia; non-Hodgkin’s 
lymphoma; Kaposi sarcoma in 
AIDS; renal cell carcinoma 
Phase I/II 
Topotecan INX-0076 Advanced cancer Preclinical 
Irinotecan 
Metabolite 
LE-SN38 Advanced cancer Phase I 
Paclitaxel EndoTAG-1, 
MBT-0206, 
Anti-angiogenic proprieties , 
breast cancer, 
Phase I 
LEP-ETU Ovarian, breast, and lung 
cancer 
Phase I 
Mitoxantrone LEM-ETU Leukemia, breast, stomach, 






1.4.2 Advantages of a liposomal drug delivery system 
Several advantages of the liposomal DDS have made it a unique biomedical 
product for the delivery of anticancer drugs (Table 1.5).  One of the factors that make 
this nano-sized carrier a preferable delivery system for anticancer drugs is its ability 
to carry larger drug content to the targeted tissues.  As mentioned before, liposomes 
are capable of encapsulating both hydrophilic and hydrophobic drugs.  As such, they 
can improve the poor water solubility of many hydrophobic drugs and thereby 
improve their availability [118, 119].  Additionally, appropriately designed liposomal 
DDS can also act as a drug depot and provide sustained release of its drug content 
[120-123].  
 
Table 1.5: Summary of some major advantages of the liposomal drug delivery system 
(Adapted from [100]). 
 
Non-ideal properties of Drugs Advantages of the liposomal DDS 
Poor Solubility Liposomes provide both hydrophilic and 
hydrophobic environments, enhancing the drug 
solubility. 
Rapid breakdown of the drug in 
vivo 
Liposomes can protect the drug from premature 




Liposomes can substantially alter the PK of the 
drug and the rapid renal clearance of small 
molecules can be avoided. 
Lack of selectivity for target 
organs 
Liposomes can increase drug concentrations in 
tumours by the EPR effect. Active targeting can 
further improve drug specificity. 
 
Similar to other nano-sized carriers, liposomes are also capable of passively 
targeting the tumours through the enhanced permeation and retention (EPR) effect.  
Under the EPR effect, macromolecules and nano-sized carriers can preferentially 




consequently retained at the tumour site due to the impaired lymphatic drainage [124].  
To take full advantage of the EPR effect or so called “passive targeting”, nano-sized 
carriers must have few important aspects to its design.  Liposomes, among all these 
nano-carriers do possess the following critical properties, which are discussed as 
follows.  
It has been reported that nano-carriers of size smaller than 200 nm can have 
efficient permeation in the tumour site although the threshold limit for extravasation is 
~400 nm [125, 126].  Alternatively, particles or small molecules less than 10 nm size 
or molecular weight less than 70000 Da are also quickly eliminated by the kidneys 
[127].  Since the size of liposomes fall within the desired size range of 10-200 nm, 
they have better chances of accumulating in the leaky tumour vasculature while also 
bypassing the normal tissues which have gaps less than 6 nm [127, 128].  
Presence of surface charges also plays a determinant role in rapid elimination 
of nano-sized carriers by the reticuloendothelial system (RES) [129].  Although 
liposomes made of anionic or cationic lipids may encounter similar fate, liposomes of 
neutral charge or slightly negative charge are less susceptible to such rapid clearance 
by RES [129].  Moreover, liposomes coated with polyethylene glycol (PEG) can also 
reduce the RES clearance due to the steric effect of the hydrophilic PEG layer [130-
134].  Presence of PEG on the liposome surface prevents protein adsorptions and 
opsonisation, and play a role in preventing liposome aggregation and fusion with 
biological membranes [135, 136].  Therefore, these PEGylated liposomes or sterically 
stabilised liposomes (stealth liposomes) are long circulating enough for efficient 
extravasation into the tumour site.  A classic example is the stealth liposomal 
formulation of doxorubicin which shows about eight times enhanced circulation 




generation of stealth liposomes not only improves the unfavourable pharmacokinetics 
of the free drug, but can also augment the therapeutic efficacy by decreasing the 
toxicity to normal tissues through EPR effect. 
 
 
Figure 1.9: A schematic diagram of nano-sized carriers accumulating in tumour sites 
by passive or active targeting. [From Ref [101]] 
 
Although, passive targeting can facilitate localisation at tumour sites, it does 
not unable to promote tumour cell uptake of the nano-sized carriers (Figure 1.9).  Site-
specific targeting or site-specific triggering are the two major phenomena which have 
been successfully utilised for tumour specific delivery of liposomes [139].  Liposomes 
attached to antibodies, antibody fragments, peptides or small molecular ligands have 
been utilised for site-specific drug delivery [140, 141].  Alternatively, use of external 
or internal stimulus such as heat, light, magnetic field, change in pH or presence of 
enzymes to generate triggered release of encapsulated content has also been employed 
for tumour specific drug release [142-145].  Success of such triggering strategies for 




formulation of doxorubicin, which is currently under phase III clinical trial for the 
treatment of non-resect able hepatocellular carcinoma [146].  
Last but not the least, liposomes are reported to have co-ordinated release of 
co-encapsulated drugs, thus maintaining the synergistic drug ratio for optimal 
therapeutic efficacy. Phase I clinical trials of co-encapsulated liposomal irinotecan 
and floxuridine as well as liposomal cytarabine and daunorubicin have demonstrated 
the success of such combinatorial drug delivery approaches [147-149].  
Although liposomal DDS has many advantages to its credit, there are some 
drawbacks encountered while translating such systems into large scale production.  
Probably the major problem faced by such systems is the stability of the encapsulated 
contents during various manufacturing processes.  Lyophilisation or freeze drying of 
liposomes has been employed to prolong the shelf life of many liposomal products 
[150, 151].  Use of organic solvents for the large scale manufacturing of liposomes 
imposes concern over human health and environment [152, 153].  Furthermore, 
liposomal products are mostly sterilised by filtration as use of heat or other 
procedures may impact liposome structure and stability of its components.  Filtration 
of large volume of liposomal products is time consuming and thereby uneconomical 
[152].  However, the success of approved marketed products such as Doxil™ and 
Myocet™ gave hope for the development of other liposomal DDS.   
Folate as a targeting ligand has several advantages. It exhibits excellent 
functional stability during manufacturing procedures, purification schemes and 
storage conditions.  Their manufacturing condition with respect to both laboratory and 
industrial scale is easy, reproducible and most importantly inexpensive [82, 154].  
However, the most noticeable aspect of folate as a targeting ligand is its lack of 




antibody fragments [155].  This may allow the repeated dosage of FR targeted (FRT) 
therapies in a clinical setting [82].  
Liposomes have been found to be a potential tool to deliver chemotherapeutic 
drugs via the FRT pathway.  It has several benefits over the drug-folate conjugates as 
conjugation may lead to compromised activity of the compound and often involves 
complex synthetic steps.  Moreover, not all drug molecules may be suitable for ligand 
conjugation due to absence of suitable functional groups.  In addition, even if the 
conjugation is easy and successful, it may not be able to release the drug after 
endocytosis due to non-cleavable linker.  More importantly, as discussed before, 
encapsulation into FRT liposomes allows the delivery of much greater drug content to 
the targeted cells in comparison to drug conjugates.  Thus, FRT through liposomes 
has emerged as an alternative approach to reduce drug toxicity and improve 
therapeutic efficacy of  several anticancer drugs [86, 156, 157].   
 
1.4.3 Different approaches to prepare FRT liposomal drug delivery systems 
Low and his group were first to synthesise the folate ligand attached lipids 
from which the FRT liposome was prepared [156, 158].  So far, this liposomal 
receptor-targeting strategy has not only been exploited for the delivery of 
chemotherapeutic agents but also for the delivery of genes and antisense 
oligonucleotides to tumour cells [123, 154, 159-161].  FRT liposomes delivered 
doxorubicin in vivo and were successful in bypassing multi-drug resistance in cultured 
tumour cells [154, 162].  Furthermore, FR targeting liposomes have been exploited 
for the intracellular delivery of paclitaxel [159], docetaxel [123], vancomycin [163], 
and 5-fluorouracil [164].  Though, the in vitro data on folate targeting suggests 




to be tumour model dependent [157].  Hence, further studies are warranted to concur 
their actual benefit over other targeting strategies.  
There are two different approaches to prepare FRT liposomes.  While both 
methods have been implemented quite successfully, each of them has its advantages 
and disadvantages.  In the first approach, preformed liposomes are first prepared and 
then used to conjugate the folate ligand onto the surface of available functional groups 
[158].  However, this procedure is difficult to control and may result in several 
unwanted by-products and untagged functional groups.  Moreover, drug-encapsulated 
preformed liposomes may confer greater stability problems, difficulty in conjugation 
and drug leakage during the different steps [82].  It also requires different conjugation 
schemes for tagging different drug-encapsulated liposomes.  
Low and Lee first proposed FRT liposomes by conjugating folate ligand on 
the surface of preformed liposomes [158].  Figure 1.10, shows the synthetic scheme 
used by Low and Lee for the preparation of FRT liposomes from preformed 
liposomes [158].  For this, maleiimide-activated liposomes were reacted with amino-
PEG-SH [158].  This newly formed amino-PEGylated liposomes were then 
conjugated to folic acid by a two-step reactions to develop the FRT liposomes (Figure 
1.10).  In the first step, N-hydroxysuccinimide (NHS) ester of folic acid (NHS-folate) 
is synthesised by reacting folic acid with N-hydroxysuccinimide [158].  In the second 
step, the previously formed amino-PEGylated liposomes are reacted with the NHS-




Figure 1.10: Preparation of FRT liposomes from preformed liposomes [Adapted from 
Ref [158]] 
 
In the second method for the preparation of FRT liposomes, folate-PEG 
conjugated lipid was previously synthesised and then incorporated into the liposome 
bilayer [155, 156].  While this procedure is much more re-producible and easy to 
perform, it may lead to the formation of liposomes which target ligand on both the 
outer and inner core.  As a result, the number of ligands available for binding may be 
lower than expected.  However, different studies have shown that even the presence 
of 1% w/v of folate-PEG-lipid in the liposome construct resulted in manifold uptake 
in FR overexpressing cells [156, 165].  Moreover, the synthesis of different folate-




and therefore its preparation and purification are not troublesome [155, 166].  Once 
synthesised, the lipid can be used in different concentrations in liposomes which can 
encapsulate different drugs without compromising their therapeutic efficacy.  This 
pioneering work by Lee and his co-workers paved the way for the development of 
different FRT liposomal DDS [156].  Figure 1.11 shows the synthetic scheme of the 
first folate-conjugated lipid from N-succinyl-distearoylphospatidylethanolamine (N-
succinyl-DSPE) as synthesised by this group [156].  Later, different types of folate-
PEG-lipids or folate-PEG-cholesterol were synthesised for the preparation of FRT 
liposomes [159, 164, 166].  In the following section, different FR targeted liposomal 











1.4.4 Delivery of anticancer drugs through FRT liposomes 
In 1995, Lee and his co-workers prepared the first FRT liposome 
encapsulating the anti-cancer drug doxorubicin (DOX) by incorporating 1% w/w of 
folate-PEG-DSPE and investigated its cytotoxicity [156].  Their results demonstrated 
significantly higher uptake (45 times) of folate-PEG-liposomal DOX by KB cells 
when compared to non-targeted (NT) liposomal DOX.  This higher accumulation of 
DOX may have led to an 86 and 2.7-times higher cytotoxicity of FRT-DOX when 
compared to NT liposomes and free drug, respectively.  These promising results from 
Lee and group led to further investigation with FRT-DOX in several other FR over 
expressing in vitro and in vivo models which has been summarised in Table 1.6.  
Meanwhile, Gabizon and his team studied the importance of a PEG spacer for 
intracellular uptake of such liposomes [167].  They synthesised different DSPE-PEG- 
folate lipids by varying the molecular mass of PEG (2000 or 3350-Da).  For the FRT 
liposomes, they used 0.5% w/w of either of this folate lipid for liposome preparation 
in absence or presence of 4% w/w of methoxyPEG2000-DSPE (Figure 1.12).  Their 
results showed that the presence of methoxyPEG2000-DSPE coating to extend the 
liposome circulation lifetime had a negative impact on the FRT liposome binding and 
uptake when DSPE-PEG2000-folate was used.  However, the uptake was improved 
when the folate-PEG spacer of 3350 Da was used along with the 4% w/w PEG 
coating.  This indicated that the presence of a longer folate-PEG spacer was essential 
to overcome the steric hindrance caused by the methoxyPEG2000-DSPE layering 
[167].  
Subsequent studies have also optimised the minimum percentage of folate-
PEG-lipid essential for substantial targeting ability.  Saul and colleagues studied the 
38
corelation of the number of targeting ligand that could be inserted into the FRT 
liposome and matched with their intracellular targeting capability [165].  FR 
overexpressing KB cells showed high uptake of DOX encapsulated in a FRT 
liposomes even with 30 and 75 ligands attached to it.  This corresponded to a 0.02% 
and 0.05% w/w of folate-PEG lipid incorporated in the liposome bilayer.  Maximum 
uptake could be observed with liposomes having 695 targeting ligands (0.5% w/w 
folate-lipid), beyond which a point of saturation was observed [165].  
 
 
Figure 1.12: Schematic diagram of liposome formulations with different folate-PEG 





Table 1.6: Examples of FRT liposomes encapsulating anticancer drugs and summary of their in vitro or in vivo performance in FR positive cell 
lines or FR positive tumour model 
 




In vivo studies/ 
pharmacokinetics 
Ref 
Doxorubicin KB cells (human oral  




Doxorubicin M109-HiFR cells 
(high FR-expressing, murine 
lung carcinoma line) 
Bypass the multidrug 
resistance 
Greater tumour growth inhibition  [162] 
Doxorubicin KB cells, subcutaneous injected 
(s.c) human xenograft model in 
mice 
--- Greater tumour growth inhibition, 
Extended circulation lifetime (i.p 
administration),  




KB cells Enhanced cytotoxicity --- [168] 
Paclitaxel KB cells Enhanced cytotoxicity Extended circulation lifetime  
(i.v administration)  
[159] 
Docetaxel KB cells Enhanced cytotoxicity Extended circulation lifetime 
(i.v administration)  
[123] 
5-Fluorouracil B16F10 melanoma cells Enhanced cytotoxicity 
Higher uptake 
Greater tumour growth inhibition 
Increase in lifespan 
[164] 





Table 1.6: Contd.  




In vivo studies/ 
pharmacokinetics 
Ref 
Doxorubicin KB-V (multidrug resistance FR 
positive cell line) 
--- dose dependent tumour 
inhibition upon  
i.v. administration 
[170] 
Doxorubicin J6456 cell (mouse ascitic tumour 
model)  
--- schedule dependent tumour 
inhibition upon  
i.p. administration  
[170] 
Doxorubicin and magnetic 
nanoparticles 




paramagnetic iron oxide  





all-trans retinoic acid 
(ATRA) 
FRβ positive leukaemia cells 
(KG-1, L1210 JF and 
recombinant CHO-FRβ) 
efficient binding and 
cytotoxicity 
significant cure rate in KG-1 
ascites leukemia, 
increased life span for mouse 
ascites leukemia models 





FRβ positive MV4-11 cells 
leukaemia cells 
efficient binding and 
cytotoxicity 




FRβ positive clonogenic acute 
myelogenous leukemia (AML) 
cells 







Table 1.6 provides a summary of different anticancer drugs encapsulated in 
FRT liposome.  Short descriptions on the important findings from these studies are 
summarised in this Table.  As evident from Table 1.6, although various FRT 
anticancer drug delivery systems have been prepared in the past decade, most of them 
have extensively studied the encapsulation of DOX.  As mentioned earlier, FR are 
over-expressed in 90% of the ovarian cancer [78].  Therefore, it is more appropriate to 
develop an FRT drug delivery system of an anticancer drug which could have 
potential application as a first-line treatment of ovarian cancer.  Though DOX is 
currently used for the treatment of ovarian cancer, it is still considered as a second-
line therapy for platinum-resistant or platinum-recurrent ovarian cancers [177].  
Moreover, existing studies till now have not investigated the effectiveness of FRT 
liposomal formulations of any anti-cancer drugs in an in vivo model of ovarian cancer.  
Thereby, it will be interesting to investigate the in vivo efficacy of carboplatin-loaded 
FRT liposomes in FR positive ovarian cancer model.  
 
1.5 Hypothesis and objective of the thesis  
Cancer Res in the last few years was focused on the development of new 
strategies to improve tumour specificity and to circumvent the intrinsic problem of 
adverse drug effect.  Currently, the marketed liposomal DDS showed promise by 
enhancing bioavailability and improving pharmacokinetics.  However, they still lack 
tumour specificity.  Among the different types of targeted liposomal DDS under 
investigation, the FR targeted liposomes have received much attention due to their 
unique ability to target the tumours through FRME. FRs are found to be 




tissues.  Hence, FR targeting through liposomes confers immense opportunities in the 
field of site-specific drug delivery for the treatment of ovarian cancer. 
Platinum compounds such as cisplatin and carboplatin are widely used as a 
first-line treatment for ovarian cancer either as single agents or in combination with 
other drugs.  Carboplatin was introduced in 1990 as an alternative to cisplatin as it 
showed reduced toxicity but similar efficacy.  To date, it is used as a first-line 
treatment for ovarian cancer as well as many other forms of cancer.  However, it has 
been found that carboplatin may cause serious side effects such as myelosuppression 
(bone marrow suppression).  
Thus, it is hypothesised that an optimised FR targeted liposomal formulation 
of carboplatin may provide improved therapeutic efficacy in ovarian cancer while 
reducing the systemic toxicity of the drug.  To test the hypothesis, the specific aims 
are as follows: 
1. To develop stable FR targeted and non-targeted liposome formulations of carboplatin. 
2. To characterise the in vitro properties of the formulations including drug loading, 
drug release, size and long-term stability. 
3. To demonstrate intracellular delivery and improved cytotoxic activity of FR targeted 
formulations in FR positive KB cells and ovarian cancer cells as compared to non-
targeted formulations. 
4. To investigate the mechanism behind the cytotoxic effects of carboplatin loaded FRT 
liposomes. 
5. To evaluate the in vivo therapeutic efficacy of the optimised formulation in an 




Figure 1.13: A hypothetical diagram of carboplatin loaded non-targeted (NT) 











glycero-3-phosphatidylcholine (DSPC),  1,2-Distearoyl-sn-Glycero-3-
Phosphoethanolamine-N-[Methoxy(Polyethylene glycol)1000] (ammonium Salt) 
(DSPE-PEG1000), 1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine-N-
[Methoxy(Polyethylene glycol)2000 (ammonium Salt) (DSPE-PEG2000)  and 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[folate(polyethylene glycol)-2000] 
(ammonium salt) (DSPE-PEG2000-folate) were obtained from Avanti Polar Lipid 
(Alabaster, AL, USA).  DiIC18 (1,1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine 
perchlorate) was obtained from Invitrogen (Carlsbad, CA, USA).  Chloroform was 
obtained from Merck & Co. (Whitehouse station, NJ, USA).  Carboplatin injection 
was purchased from Teva Pharmaceuticals Industries Ltd.  (Petah Tikva, Israel).  
Carboplatin (powdered drug), 10% buffered formalin solution, glacial acetic acid, 
platinum atomic absorption standard solution, Sephadex G-50 size exclusion gel, D-
(+) sucrose, D-(+)-trehalose Dihydrate, D-(+) glucose and all other chemical reagents 
were purchased from Sigma Aldrich (St, Louis, MO, USA). 
3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) and 
dimethyl sulfoxide (DMSO) were purchased from MP Biomedicals, Inc (Singapore). 
U0126 was purchased from Cell Signalling Technology (Beverly, MA, USA) and 




from Alexis (San Diego, CA, USA), pERK42/44 was from Cell Signalling 
Techonlogy and -actin was from Sigma Aldrich (St. Louis, MO, USA).  Mouse 
Alexa-Fluor 594 antibody was obtained from Invitrogen (Carlsbad, CA, USA).  Goat 
anti-mouse IgG and goat anti-rabbit IgG secondary antibodies conjugated with 
horseradish peroxidase were from Pierce Biotechnology (Rockford, IL, USA). 
Heparin was purchased from Hanlim Pharm. Co., Ltd. (Seoul, Korea).   
 
2.1.2 Cell lines 
KB cells (FR positive human oral carcinoma cell line) and A549 cells (FR 
negative lung cancer cell line) were obtained from American Type Culture Collection 
(Manassas, VA, USA).  FR positive human ovarian cancer cell line IGROV1 was a 
gift from Prof. Larry H. Matherly, Wayne State University, School of Medicine, 
Detroit, MI, USA.  Other ovarian cancer cell lines such as SKOV3 and OVCAR-3 
were also obtained from American Type Culture Collection (Manassas, VA, USA).  
All cell lines were cultured as monolayers in 75-cm2 tissue culture flasks in folate-free 
RPMI 1640 media (GIBCO, Grand Island, NY, USA), supplemented with 100 U/mL 
penicillin, 100 μg/mL streptomycin and 10 % fetal bovine serum (FBS; HyClone 
Laboratories, Logan, UT, USA), and were maintained in a humidified atmosphere 
containing 5% CO2 at 37C. 
 
2.1.3 Mice  
Six to eight weeks-old female CB-17 SCID mice (severe combined 
immunodeficiency) were purchased from Charles River Laboratories (Wilmington, 
MA, USA), and housed in micro-isolator cages in a pathogen free animal bio-safety 




Bethlehem, PA, USA) from two weeks before the start of the experiment.  All 
procedures involving the use and care of mice were performed humanely in 
conformity with the National Advisory Committee for Laboratory Animal Research 
(NACLAR) guidelines.  All studies were conducted according to the protocols 
approved by the National University of Singapore Institutional Animal Care and Use 
Committee (IACUC). 
 
2.2. Preparation of liposome  
2.2.1 Preparation of non-drug loaded liposomes 
All liposome formulations were prepared by extrusion method as described by 
Mayer et al [178].  The FRT liposomes were made of DPPC/ DSPE-PEG1000/DSPE-
PEG2000-folate (DPPC-FRT) or DSPC/ DSPE-PEG1000/DSPE-PEG2000-folate (DSPC-
FRT) at a molar ratio of   95: 4.8: 0.2.  The non-targeted (NT) liposomes were made 
of DPPC/DSPE-PEG1000 (DPPC-NT) or DSPC/DSPE-PEG1000 (DSPC-NT) in 95:5 
molar ratios.  All lipids were individually dissolved in chloroform and then mixed 
together in the appropriate proportions.  Chloroform was subsequently evaporated 
under a stream of nitrogen gas, and the sample was then subjected to vacuum for ~3 h 
to remove the residual solvent.  The resultant lipid film was hydrated with gentle 
stirring for 1 h in 0.9 % NaCl (pH 7.5) so that the final lipid concentration was 80 
mg/mL.  The resultant multilamellar vesicles (MLVs) were extruded ten times 
through 80-nm and 100-nm polycarbonate membranes using a heated thermobarrel 
extruder (Northern Lipids, Vancouver, BC, Canada).  Both hydration and extrusion 
were performed at a temperature of 55 ± 2C for DPPC-NT and DPPC-FRT 




diameter and polydispersity of each liposome batch was analysed by Zetasizer model 
3000 HS (Malvern Instruments, Malvern, WR, UK) at 632 nm.  
For lyophilisation of cholesterol free PEGylated liposomes, another lipid 
composition was used along with the previously mentioned liposomes composition.  
These were made of DPPC/DSPE-PEG2000 in the molar ratio of 95:5.  All liposomal 
samples, drug-loaded, non-drug loaded or lyophilised liposomes were stored at 2-8°C 
for future studies. 
 
2.2.2 Lipid content analysis by phosphate assay 
Lipid concentration in liposomes was determined by phosphate assay [179, 
180].  Briefly, 700 µL of perchloric acid was added to both standards and samples 
were subjected to heating at 190°C for 1 h.  Upon cooling, 700 µL of fiske solution 
and 7 mL of Ammonium molybdate solution was added and heated for another 20 
min at 100°C.  Absorbance was measured at 830 nm with a UV-Vis 
spectrophotometer (Shimadzu UV1601, Kyoto, Japan).  Lipid concentration was 
determined by linear standard curve resolution method.  
 
2.2.3 Drug loading and analysis 
For loading carboplatin into the pre-formed liposomes, the passive 
equilibration method was employed [181].  Briefly, pre-warmed carboplatin powder 
was mixed with the liposomes at a drug-to-lipid (D/L) weight ratio of 0.25:1 and was 
incubated at 55 ± 2C (for DPPC liposomes) or at 65 ± 2C (for DSPC liposomes) 
with gentle mixing for the required time.  After incubation, the drug-loaded liposome 
was cooled to room temperature.  At indicated time points, the liposomal formulations 




column pre-equilibrated with 0.9 % NaCl (pH 7.5) by centrifugation at 680  g for 3 
min.  The liposome eluted in the void was collected and further analysed for final 
drug and lipid content. Carboplatin content was analysed by atomic absorption 
spectroscopy (AAS) using a Perkin Elmer analyst 100 model (Perkin Elmer, 
Waltham, MA, USA) attached to a graphite tube atomiser (Perkin Elmer analyst 100 
HGA 800 model).  Samples were diluted with 1% nitric acid to yield a final platinum 
concentration in the range of 50-250 ng/mL [182].  The analysis was performed at a 
wavelength of 265.9 nm and the temperature was calibrated to be of 90ºC for 30 s, 
120ºC for 10 s, 1100ºC for 15 s, 2700ºC for 5 s (reading time) and 30ºC for 40 s.  The 
standard curve was plotted using a platinum standard solution.  All measurements 
were made in duplicates. Final D/L ratio is calculated from the lipid concentration 
obtained from phosphate assay and carboplatin concentration obtained from AAS. 
Loading efficiency (%) of the liposomes is calculated from the formula below:  
Encapsulation or Loading efficiency ሺ%ሻ  ൌ  Final D/LInitial D/L  X 100 % 
 
2.2.4 In vitro drug release studies  
The release of encapsulated carboplatin was determined in sink condition by 
dialysing 0.5 mL samples in mini dialysis cassettes (Pierce, Rockford, IL, USA; 3.5K 
molecular weight cut-off) against 1 L of phosphate buffered saline (PBS; pH 7.4) at 
37ºC for 72 h with constant stirring.  Separate dialysis cassettes were used for each 
time points.  Amount of carboplatin remaining in the liposome samples were 
measured by AAS as mentioned earlier.  Decrease in carboplatin content at various 




Release studies were also done with reconstituted lyophilised liposomes 
loaded with carboplatin to determine the effect of lyophilisation on carboplatin 
release.  
 
2.3. Flow analysis for FR expression  
KB cells, A549 cells, IGROV1 cells, OVCAR-3 cells, SKOV3 cells were 
harvested separately  using trypsin and 2  105 cells were incubated with 100 L of 
anti-FR antibody at a final concentration of 0.2 mg/mL at 4C for 1 h with gentle 
rotation.  After 1 h of incubation, cells were pelleted at 10 000 rpm for 5 min, and 
washed twice with 1 mL of PBS before incubating with 4 g/mL of Alexa-Fluor 594 
at 4C for 20 min with gentle shaking.  At the end of incubation, cells were washed 
twice with PBS before analysis with Beckman Altra FACS (Beckman Coulter, Brea, 
CA, USA) with 10 000 events in each group being collected. 
 
2.4. In vitro cytotoxicity assay 
For MTT assay, cells were seeded in 96-well plates at a density of 3000 cells 
(KB cells) and 5000 cells (A549 cells, IGROV1 cells) per well respectively, and 
allowed to attach overnight.  The following day, the culture medium was replaced 
with 200 μL of fresh medium added with the required concentrations of carboplatin in 
the free or liposome-encapsulated form as specified in each experiment.  1 mM free 
folic acid was added to the media, as specified.  The plates were further incubated for 
72 h at 37°C.  MTT (1 mg/mL) was added to the cells, and after 4 h of incubation, the 
precipitated purple formazan was solubilised in DMSO.  Absorbance at 570 nm was 




Switzerland).  Cancer cell viability was calculated from the absorbance values based 
on the following equation: 
Cell viability ሺ%ሻ
ൌ ሾܣܾݏ݋ݎܾܽ݊ܿ݁௧௘௦௧ െ ܣܾݏ݋ݎܾܽ݊ܿ݁௕௟௔௡௞ሿሾܣܾݏ݋ݎܾܽ݊ܿ݁௨௡௧௥௘௔௧௘ௗ ௖௢௡௧௥௢௟ െ ܣܾݏ݋ݎܾܽ݊ܿ݁௕௟௔௡௞ሿ ൈ 100% 
where, Absorbance test, Absorbance blank, and Absorbance untreated control represent the 
absorbance readings from the drug-treated wells, wells with only media and the 
untreated wells, respectively.  The IC50 (half maximal inhibitory concentration) values 
were calculated from the cell viability data using CalcuSyn 3.0 software (Biosoft, 
Cambridge, UK). 
For cell viability assay in the presence of MEK/ERK inhibitors, 5000 KB cells 
per well were plated 24 h prior to the assay and treated as mentioned above with or 
without 10 µM U0126 or 20 µM PD98059.  Relative increase in viable cell fraction 
was calculated by the following equation:  
Relative increase in VCF ሺ%ሻ ൌ  VCF୵୧୲୦ ERKିI – VCF୵୧୲୦୭୳୲ ERKିI VCF୵୧୲୦୭୳୲ ERKିI  X 100 % 
where, VCF and ERK-I indicates viable cell fraction and ERK inhibitor, respectively.  
 
2.5. Cellular uptake of fluorescent liposomes 
For the preparation of fluorescent tagged liposomes, the lipid film composition 
of FRT-DiI liposomes was DPPC/DiI/DSPE PEG1000/DSPE-PEG2000-folate at a molar 
ratio of 94.5: 0.5: 4.8: 0.2, whereas for NT-DiI liposome was DPPC/DiI/DSPE 
PEG1000 at a molar ratio of 94.5: 0.5: 5.  Liposome preparation method was the same 
as before. DiI being light sensitive, all the steps were carried out either in the dark or 




KB cells (1.5 X 106) or IGROV1 cells (1 X 106) were plated in 35 mm dish 
and allowed to attach overnight.  On the following day, 0.005% of FRT-DiI liposomes 
or NT-DiI liposomes were added to the cells and incubated at 37°C for 4 h and 24 h, 
respectively. FRT-DiI liposomes were also added in presence of 1 mM free folic acid 
to determine the effect of FR blockage.  At the end of incubation period, the cells 
were washed three times with cold PBS to remove the unbound liposomes and 
visualised under fluorescent or phase contrast condition using Nikon ECLIPSE 
TE2000-U microscope (Nikon Instruments Inc., Melville, NY, U.S.A.).  Images were 
captured using Nikon Digital Camera DXM 1200.  
 
2.6. Cellular platinum uptake 
KB cells (1.5 X 106), A549 cells (1.5 X 106) or IGROV1 cells (1 X 106) were 
plated in 35-mm dish respectively, and allowed to attach overnight.  After 24 h, 250 
µM of free carboplatin or carboplatin loaded NT or FRT liposomes were added to the 
cells. On the following day, 250 µM of the free or liposome-encapsulated carboplatin 
were added to the cells.  After treatment for 24 h, the cells were harvested and 
pelleted at 1200 rpm for 3 min, followed by two washes with PBS.  Cell count was 
performed, and 1  106 KB cells or 1  105 A549 cells or 1  105 IGROV1 cells were 
digested in 50 µL concentrated nitric acid respectively, followed by heating at 85C 
for 1 h.  Cell debris was removed by centrifugation at 13000 rpm for 15 min.  Sample 
was then diluted 8-folds (KB cells or A549 cells) or 4-folds (IGROV1 cells) with 
double distilled water before the determination of platinum content by AAS. 
 




1.5  106 KB cells were plated in 35-mm dish.  On the following day, 250 M 
of the free or liposome-encapsulated carboplatin was added to the cells and treated for 
48 h.  The cells were washed with PBS and lysed in 600 L nuclear lysis buffer (10 
mM Tris pH 8.2, 400 mM NaCl, 2 mM EDTA, 0.5 % SDS, 0.2 mg/mL proteinase K) 
for 4 h at 37C. Saturated NaCl solution (340 L) was then added to the cell lysate, 
followed by vigorous shaking and centrifugation at 13000 rpm for 30 min.  The 
supernatant containing the DNA was transferred to a fresh tube containing 1.2 mL 
absolute ethanol and mixed gently.  DNA was pelleted by centrifugation at 4000 rpm 
for 30 min and washed three times with 70% ethanol.  Finally, the DNA pellet was 
air-dried, dissolved in water and quantified at absorbance 260 nm by UV 
spectrophotometry. DNA purity was determined by calculating the ratio of 
absorbance at 260 nm to absorbance at 280 nm, and a ratio of 1.7-1.9 indicated pure 
DNA.  For DNA-platinum adduct formation, DNA was diluted with 4% v/v nitric 
acid to a final concentration of 1% v/v nitric acid, and heated at 85C for 1 h.  
Insoluble particles were removed by centrifugation at 13000 rpm for 15 min.  The 
platinum content of the sample was then determined by AAS. 
 
2.8. Western blot analysis  
KB cells were plated in 6-well plate at a density of 1.5  106 cells per well and 
allowed to attach overnight.  The following day, cells were treated with 250 M 
carboplatin in the free or liposome-encapsulated form for 24 h.  In another study, the 
cells were treated with increasing concentrations of carboplatin (62.5 M, 125 M 
and 250 M) encapsulated in FRT liposomes in the presence or absence of 50 M 




increasing concentration of non-drug loaded FRT liposomes (1.25 to 10 mM) to 
determine its effect on ERK activation.  
After treatment, floating cells and attached cells were lysed using ice-cold 
lysis buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 10 mM EDTA, 1% (v/v) NP-40, 20 
mM sodium fluoride, 5 mM sodium pyrophosphate, 1 mM sodium vanadate, 10% 
(v/v) glycerol, protease inhibitor cocktail).  Cell debris was removed by centrifugation 
at 20 000  g for 20 min at 4C.  Protein was quantified using Bio-rad protein assay 
dye reagent, and equal amount of protein (50 μg) was electrophorosed on 10% SDS-
polyacrylamide gels, followed by transferring onto nitrocellulose membrane.  
Membrane was blocked with 5% v/v milk in Tris-buffered saline with Tween 20 (150 
mM NaCl, 10 mM Tris-HCL, pH 7.5, 0.1 % Tween 20) before probing with primary 
antibody according to the manufacturer’s instructions.  The membrane was then 
probed with the corresponding secondary antibody conjugated with horseradish 
peroxidase for 1 h.  Protein bands were detected by enhanced ECL reagent (Pierce) 
and visualised by autoradiography film (Thermo Scientific, Waltham, MA, USA).  
For re-probing, blots were stripped with Restore Western Blot stripping buffer 
(Thermo Scientific, Waltham, MA, USA).  For densitometric analysis, the relative 
intensity of the bands representing pERK were quantified using Image Gauge-4 
software (Fuji film Co. Ltd, Tokyo, Japan) and were normalised to the actin bands.  
 
2.9. Animal study 
2.9.1 In vivo efficacy study 
The in vivo efficacy study was conducted according to the protocol approved 
by IACUC, following NACLAR guidelines.  Twenty four female SCID mice were 




days of tumour inoculation, mice were randomly divided into 4 groups (6 per group) 
and treated i.p. with (1) saline, (2) free carboplatin, (3) carboplatin loaded NT 
liposomes, (4) carboplatin loaded FRT liposomes.  Carboplatin was administered at a 
dose of 15 mg/kg for a total of 6 times in 3 weeks on a Thursday-Monday schedule 
(day 14, 18, 21, 25, 28, 32).  Body weights of the mice were monitored at least thrice 
weekly from the date of arrival until day 60, whereas every day during treatment with 
carboplatin according to IACUC guidelines.  All mice were monitored daily for a 
decrease in physical activity, signs of pain and other signs of disease progression.  
Severely ill animals or animals showing weight loss or gain in excess of 20% were 
euthanised by an overdose of carbon dioxide (CO2).  Animal survival was recorded 
daily from the day of tumour cell inoculation (day 0).  Endpoint was stipulated at 60 
days after cancer cell inoculation according to the regulations of the IACUC.  Mice 
surviving until the end of the experiment were termed as long-term survivors (LTS) 
and euthanised on day 60. Percentage weight change at nadir was calculated from the 
following equations: 
Weight change at nadir ሺ%ሻ ൌ ሾI୬୧୲୧ୟ୪ ୵ୣ୧୥୦୲ ୠୣ୤୭୰ୣ ୲୰ୣୟ୲୫ୣ୬୲ିWୣ୧୥୦୲ ୟ୲ ୬ୟୢ୧୰ሿI୬୧୲୧ୟ୪ ୵ୣ୧୥୦୲ ୠୣ୤୭୰ୣ ୲୰ୣୟ୲୫ୣ୬୲ ൈ 100%  
 
2.9.2 Dry weight of spleen 
Spleen was excised from the IGROV1 inoculated and treated mice (saline 
control, free carboplatin, NT liposome, and FRT liposome) after being euthanised.  
Spleen was also excised from four normal SCID mice without tumour cell inoculation 
(without tumour group).  After collection, the tissues were fixed in 10% buffered 
formalin solution and stored until analysis.  On the day of analysis, spleen was blotted 
in blotting paper to remove the formalin residues and air-dried for 8 h.  Weight of 




Goettingen, Germany).  Weight of spleen was compared among groups by dividing 
the spleen weight with body weight of the individual mice.  
 
 
2.9.3 Assessment of plasma concentration of carboplatin after weekly dosing 
All mice undergoing efficacy study were subjected to blood collection 24 h 
after the weekly dosing of carboplatin (free from, NT liposome, FRT liposome).  
Approximately, 50 μL of blood was collected from each mouse in heparinised tubes 
by facial vein bleeding technique.  This non-terminal procedure allowed repeated 
sampling using alternate side of the face at the area of mandible. Blood was collected 
only once every week (at 19th, 26th, and 33rd day) to assess the concentration of Pt in 
blood after the administration of two doses of chemotherapy had been administered.  
Plasma was separated by centrifugation at 13000 rpm for 15 min and stored at −80°C 
until analysed.  Pt content in plasma was determined by AAS according to the 
procedure described by Bandak’s group [184].  Briefly, the plasma samples were 
dissolved with concentrated nitric acid at 85°C for 1 h in a MG-2300-EYELA Al-
block heater (Bohemia, NY, USA).  The debris were pelleted by centrifugation at 
13000 rpm for 15 min.  The resultant supernatant was diluted with double distilled 
water and analysed by AAS as described above.  
 
2.9.4 Histopathology 
Lungs, liver, and kidneys were excised from all groups of mice undergoing 
chemotherapy for histopathological evaluation of the tissue samples.  The tissues were 




sectioned at 4 µm for haematoxylin and eosin (H & E) staining.  Tissues from at least 




2.10. Lyophilisation of liposomes and reconstitution  
Cryoprotectant glucose, sucrose or trehalose was added to liposome samples at 
sugar: lipid molar ratio of 3:1 or 5:1 or 7:1.  The resultant liposome samples were 
frozen at -86°C for 8 h (ULT Freezer, Thermo Electron Corporation Forma, Waltham, 
MA, USA) and subsequently lyophilised for next 48 h (Christ Alpha 2-4 LD Plus 
Freeze Dryer, Osterode, Germany).  Lyophilised samples were reconstituted to 
original volume using milliQ water as and when required.  
 
2.11. Long term stability studies 
Drug content, size and PI of carboplatin loaded FRT and NT liposomes were 
evaluated for a period of 1 yr. Size and PI were measured according to the method 
described above.  For drug content analysis; all liposome samples were separated 
from the released drug by Sephadex G-50 spin columns as mentioned before.  The 
final drug and lipid content were analysed according to the previously described 
method.   
For long-term stability of lyophilised liposome samples, 500 µl of liposomes 
were aliquot into small vials, cryoprotected with sucrose (sugar: lipid molar ratio of 
5:1) and lyophilised according to the procedure mentioned before.  For long-term 
storage, the samples were stored at -20°C. At required time-points of 1, 15, 30, 60, 




size and PI were measured as described in section 2.2.  For stability upon 
reconstitution, the once reconstituted samples were stored at 4 ± 2°C and analysed for 
change in size and PI at different time points of 1, 15, 30 and 60 days, respectively.  
 
 
2.12. Optical imaging  
2.12.1 Field emission scanning electron microscopy  
Surface morphology of lyophilised liposomes with or without different types 
of cryoprotectants was examined by field emission scanning electron microscope 
(FESEM).  Lyophilised samples (with or without cryoprotectants) were fixed on the 
aluminum stubs and coated with platinum for 60 s in an auto fine coater (JFC-1600 
(JEOL)).  Afterwards, images were taken at an operating voltage of 5 kV in JOEL 
field emission scanning electron microscope (JSM-670-1F). 
 
2.12.2 Cryogenic field emission scanning electron microscopy  
Size and shape of empty liposomes or lyophilised liposomes were examined 
by cryogenic field emission scanning electron microscope (cryo-FESEM).  
Approximately 2-3 drops of formulation (~30 µL) were placed on a copper stub and 
frozen in nitrogen slush at -196 °C.  Samples were then stored in liquid nitrogen and 
transferred into the cryo preparation chamber (GATAN ALTO 2500, Oxford, UK) 
attached to a FESEM (JEOL JSM-6700F, Tokyo, Japan).  The sample was freeze-
fractured and sublimed at -95 °C for 30 s.  The fractured sample was sputter-coated 
with platinum for 120 s in the Cryo preparation chamber and then introduced onto the 






2.12.3 Cryogenic transmission electron microscopy 
Morphological features of empty and drug loaded FRT liposomes were taken 
through cryogenic transmission electron microscopy (Cryo-TEM).  Briefly, diluted 
liposome samples were placed onto a copper grid (~3.8 µL) and blotted to form a thin 
aqueous layer.  Subsequently, the sample was flash frozen in liquid ethane and 
transferred to Cryo-TEM grid holder pre-cooled and maintained in liquid nitrogen.  
This Cryo-TEM specimen holder was transferred to a JEOL JEM 2010F TEM (JOEL 
Ltd, Tokyo, Japan) for analysis at a voltage of 120 kV. 
 
2.13. Moisture content analysis using Karl Fischer titration 
Moisture content of the lyophilised samples was measured by Karl Fischer 
Titration instrument.  Briefly, instrument was calibrated for 3 h. Samples were 
accurately weighed and quickly placed inside the titration chamber.  The sample was 
dissolved at 100 rpm for 200 s. Moisture content was recorded from the instrument. 
 
2.14. Differential scanning calorimetry  
Differential scanning calorimetry (DSC) measurements were done on a DSC-
2920 Differential Scanning Calorimeter (TA Instruments, New Castle, Delaware, 
USA) and an empty standard aluminum pan was used as a reference.  Liposome 
samples (~5 µl) were placed in DSC aluminum pans and measurements were done at 
a temperature scan range from 25-60 °C at a heating rate of 10°C/min under stream of 
air.  Lyophilised liposomes were reconstituted with water before analysis.  The results 
were analysed by Thermal Solution Software Version 1.4E (TA Instruments, New 




temperature (Tm).  All scans were done in duplicates and at least three different 
batches of liposome formulations were evaluated.  Reproducibility of DSC curves 
after each scan was good. For the DSC curve plot, same y-axis dimensions were used 
but the positions of the curves were adjusted for better clarity. 
 
2.15. Statistics 
All experiments were carried out in triplicates, unless otherwise stated.  
Results were expressed as mean ± S.E.M.  Statistical analyses were performed with 
one-way analysis of variance (ANOVA) and the post-hoc Newman-Keuls test using 
GraphPad Prism Version 2.00 (San Diego, CA, USA).  Paired t-test was adopted 
where applicable.  Survival curves and probabilities were estimated using the Kaplan-
Meier technique by the MedCalc statistical package version 11.4.4.0 (Mariakerke, 
Belgium).  A log-rank test for comparisons was used when required.  A p-value of 







DEVELOPMENT AND IN VITRO CHARACTERIZATION OF 
FOLATE RECEPTOR TARGETED LIPOSOMES 
 
3.1. Introduction 
Given its importance in the delivery of anti-cancer therapeutics, liposomal 
delivery systems have been developed for the Pt-based compounds [117, 134].  
Among the Pt drugs used for ovarian cancer treatment, SPI-077, which is the 
PEGylated liposomal cisplatin formulation, was the first to enter early-phase clinical 
trials.  However, this formulation could not succeed due to insufficient release of the 
drug from the liposome carrier despite high liposomal drug accumulation in the 
tumour site [184, 185].  This necessitated the development of liposomal systems 
which could be specifically internalised by the cancer cells, thereby delivering the 
drug content directly to the molecular targets within the cancer cells [186, 187].  As 
discussed in chapter 1, intracellular drug delivery could be achieved through receptor-
mediated endocytosis of liposomes conjugated with targeting ligands such as folic 
acid [141, 188].   
Therefore, in this chapter, we have developed FRT liposomal formulations of 
carboplatin and compared it to NT liposomal formulation as well as the free drug.  
The liposome formulation was optimised for lipid composition and drug loading time. 
Carboplatin, an analogue of cisplatin, is a hydrophilic drug [44, 189].  Earlier methods 
to encapsulate cisplatin in cholesterol containing liposomes resulted in insignificant 




employed the passive equilibration method to load carboplatin within the cholesterol-
free liposomes [181].  Drug loading by passive equilibration method is highly 
dependent on the membrane permeability of phosphatidylcholine (PC)-based vesicles.  
At a temperature above the phase transition temperature (Tm) of the lipids, the 
lipophilic membrane has an expanded vesicle area  which facilitates in the 
accumulation of hydrophilic drug molecules within the liposomes [190].  When the 
temperature is reduced below the Tm, carboplatin remains trapped within the 
liposomes.  Based on this principle, carboplatin was loaded into FRT and NT targeted 
liposomes.  
The optimised formulations were analysed for size, final drug content, drug 
release and in vitro cytotoxicity in FR overexpressing KB cells.  This FR positive 
human oral carcinoma cell line has been the gold standard for evaluating FRT 
therapeutics for more than two decades.  This fact is also evident from Table 1.6 
(chapter 1), as most of the studies have used KB cells due to the ubiquitous presence 
of FRα in these cells.  Therefore, in vitro evaluation of FRT liposomes in KB cells 
was considered as the first step towards the investigation of its therapeutic efficacy in 
FR positive tumours.  Further studies were performed on FR positive ovarian cancer 
model in chapter 4.  It was anticipated that an optimised FRT liposomal formulation 
of carboplatin would exhibit enhanced therapeutic activity in these FR overexpressing 
cancer cells compared to free carboplatin or PEGylated liposomal carboplatin.  As 
such, we have also studied the mechanism of the enhanced cytotoxicity of carboplatin 





3.2. Results  
3.2.1 Carboplatin encapsulation in NT and FRT liposomes  
For initial screening, saturated lipid DPPC or DSPC was chosen as the bulk 
component, whereas the folate-conjugated lipid DSPE-PEG2000-folate and DSPE-
PEG1000 were chosen for effective binding and pegylation, respectively.  The different 
FRT liposomes are hereby denoted as DPPC-FRT and DSPC-FRT, whereas the NT 
liposomes are denoted as DPPC-NT and DSPC-NT, respectively, based on the bulk 
lipid used.  The lipids molar ratio was determined based on the results found by Woo 
et al. encapsulating cisplatin by passive equilibration method [181].  Based on 
observations from the previous work, an initial drug to lipid ratio (D/L) of 0.1: 1 
(w/w) was selected for carboplatin loading into DPPC-NT liposomes.  The 




Figure 3.1: Time dependent accumulation of carboplatin into DPPC-NT liposomes 
with an initial drug-to-lipid molar ratio of 0.1:1.  Results shown are the mean ± S.E.M 





As can be seen from Figure 3.1, rapid loading of carboplatin occurred within 
30 min of incubation and the maximum D/L loading was observed at 2 h (0.011 ± 
0.0024 (w/w)) although it was not significantly higher than the D/L ratio achieved 
within 1 h (0.0106 ± 0.0024 (w/w)).  No further improvement in drug loading was 
observed after 3 h (p > 0.05), and it seemed that loaded drug may have leaked out 
following longer incubation time.  The final D/L ratio obtained was approximately 
0.009 ± 0.0033 (w/w) with a loading efficiency of about 9-12%.  
This percentage loading obtained was similar to the loading efficiency of 
cisplatin liposomes described by Woo et al [181].  Using the passive equilibration 
method, the hydrophilic drugs were encapsulated within the inner aqueous core of 
liposomes by diffusing through the lipid bilayered structure, therefore the external 
carboplatin concentration might have a critical role to play in drug loading [191].  
Hence, to improve the drug encapsulation, the external carboplatin concentration for 
drug loading was increased from 10mg/ml to 20mg/ml with an initial D/L ratio of 
0.25:1 (w/w).  Accumulation of carboplatin in different FRT and NT liposome 
formulations were determined over time.   
As demonstrated in Figure 3.2, rapid loading of carboplatin occurred within 15 
min of incubation, and maximum loading was achieved at 60 min for the different 
formulations.  The final D/L ratios achieved in the DPPC-NT and the DSPC-NT 
liposomes were 0.062±0.004 (w/w) and 0.040±0.006 (w/w), respectively.  Similar 
drug loading was achieved in DPPC-FRT and DSPC-FRT, with final D/L ratios of 
0.057±0.006 (w/w) and 0.036±0.003 (w/w), respectively.  The results suggest that 
DPPC-based liposome systems had slightly higher drug encapsulation than DSPC-
based liposomes, although the difference was not statistically significant (p > 0.05).  
This lower drug entrapment could be attributed to the increased hydrophobicity 
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resulting from the increased chain length of the phospholipid DSPC which possibly 
did not favor entry of the hydrophilic drug, carboplatin.  The encapsulation 
efficiencies of carboplatin into DPPC-NT, DPPC-FRT, DSPC-NT and DSPC-FRT 
liposomes were calculated to be 24.8%, 22.8%, 16.0% and 14.4%, respectively.  The 
final D/L weight ratios of DPPC-NT and DPPC-FRT liposomes were equivalent to 
molar ratios of 0.130±0.009 and 0.122±0.012, respectively, which are higher than 
those in the liposomal cisplatin formulation SPI-077 (molar ratio of 0.014) and in the 




Figure 3.2:  Time dependent accumulation of carboplatin into different liposomes via 
passive equilibration method.  Carboplatin encapsulation was determined in DPPC-
NT (♦); DPPC-FRT (■); DSPC-NT (▲); DSPC-FRT (●) liposomes. Results shown 







3.2.2 Size determination by Zetasizer  
The size range of liposomes is closely related to the mechanism of liposome 
uptake by the reticulo-endothelial system and rapid clearance by glomerular filtration 
[193].  In addition, highly polydispersed liposomes can cause embolism due to the 
risk of particle aggregation during systemic administration [194].  Liposomal size also 
plays a determinant role in passive accumulation of liposomes in tumour vasculature 
via EPR effect [193].  Previous results have demonstrated that liposomes between 
100-200 nm are most stable in vivo and exhibit better drug retention property than 
larger liposomes having the same lipid composition.  Moreover, size and 
polydispersity are parameters indicative of liposome stability, whereby an increase in 
size indicates aggregation and a decrease in size indicates degradation of the 
liposomes.  
Figure 3.3 shows a representative size distribution curve before and after drug 
loading into DPPC-NT liposomes as determined by Zetasizer.  As shown in Table 3.1, 
the size of all liposomal formulations was within 100-110 nm with a narrow 
polydispersity index, indicating uniform size distribution. DPPC-NT and DPPC-FRT 
liposomes exhibited 102.71 ± 2.55 nm and 103.75 ± 2.67 nm in diameters and, the 
polydispersity index was 0.103 ± 0.018 and 0.099 ± 0.009, respectively.  Change in 
size after drug loading was insignificant, which suggested that carboplatin loading did 
not induce liposome aggregation.  
 
Table 3.1:  Size and polydispersity index (PI) of different liposomes 
 DPPC-NT DPPC-FRT DSPC-NT DSPC-NT 
Size 102.71 ± 2.55 103.75 ± 2.67 105.25 ± 7.25 108.13 ± 5.25 
PI 0.103 ± 0.018 0.099 ± 0.009 0.111 ± 0.012 0.131 ± 0.024 
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Results shown are the mean ± S.E.M from at least three independent experiments. 
 
 
Figure 3.3: Size distribution profile of DPPC-NT liposome before (left) and after 
(right) carboplatin loading. Representative images from at least 3 batches of 
formulation have been shown. 
 
3.2.3 Optical imaging of drug loaded liposomes by Cryo-TEM 
Cryo-TEM was performed to visualise the morphology of carboplatin loaded 
and non-drug loaded FRT liposomes.  As expected, substantial difference between 
empty and drug-loaded liposomes could be seen in Cryo-TEM images.  As shown in 
Figure 3.4, drug-loaded liposomes showed an inner dense core, whereas empty 
liposomes did not show any dense core.  It is likely that the encapsulated carboplatin 
was precipitated within the liposome core after drug loading and subsequent cooling 
to room temperature.  This result was in contrast with previous observations where 
cisplatin encapsulated liposomes did not show any precipitation inside the liposome 




carboplatin are electron-dense compounds [181].  However, both empty and 
carboplatin loaded liposomes showed similar morphology, spherical shape and size of 
about 100nm.  
 
 
Figure 3.4: Cryo-TEM electron micrographs of empty and carboplatin-loaded FRT 
liposomes (DPPC-FRT) prepared using the passive equilibration technique.  
 
3.2.4 In vitro drug release from FRT and NT liposomes in PBS 
The release profiles of carboplatin from DPPC-NT, DPPC-FRT, DSPC-NT 
and DSPC-FRT liposomes were characterised. Figure 3.5 depicts the release profiles 
of carboplatin from FRT and NT liposomes following dialysis in 1 L of phosphate 
buffer saline (PBS) at 37 °C.  Typically, the release profile of carboplatin in different 
formulations displayed a burst effect where approximately 20-30 % of the drug was 
released within the first 8 h.  Thereafter, carboplatin released from the formulations 
followed a sustained release pattern where less than 30-40 % of the drug was released 






Figure 3.5:  Cumulative release of carboplatin from DPPC-NT (♦); DPPC-FRT (■); 
DSPC-NT (▲); DPPC-FRT (●) liposomes under sink condition (1:1000 v/v) in 1 L 
PBS at 37 °C. Results shown are the mean ± S.E.M from at least three independent 
experiments. 
 
Although the drug release profiles were similar in all types of formulation 
without did not indicate any significant difference, DPPC-NT and DPPC-FRT 
liposomes exhibited slight controlled release profiles of carboplatin, not shown in 
DSPC counterparts. Interestingly, no significant difference in release pattern was 
observed for the different NT and FRT formulations at different time points (p>0.05).  
Taken together, the results indicated that the inclusion of the DSPE-PEG2000-folate did 
not alter the membrane permeability of the liposome. 
Since DPPC based liposomes (DPPC-FRT and DPPC-NT) showed higher 
drug loading in comparison to DSPC based liposomes but without any significant 
difference in drug release pattern, all further studies were done with DPPC-FRT and 
DPPC-NT liposomes.  Henceforth, DPPC-FRT and DPPC-NT liposomes will be 




Upon in vitro characterisation of the FRT and NT liposomes, the aim of the 
project was to test the third hypothesis of the thesis.  As mentioned before, KB cells, 
the well-established model of FR positive human cancer cells were chosen for 
evaluation and comparison with NT formulation and free drug.  Other research groups 
have previously reported human lung cancer A549 cells as a FR negative cell line 
[195, 196]. Therefore, this was taken as a negative control to determine the selectivity 
of the optimised FRT formulation.  
 




Figure 3.6:  FR expression in FR positive KB cells (A) and FR negative A549 cells 
(B). The control panel represents cells without incubation with primary antibody. 





FR expressions in the FR positive KB cells and FR negative A549 cells were 
verified by flow cytometric analysis (Figure 3.6).  As expected, KB cells showed 
amplified expression of FR (>90%), whereas A549 showed negligible expression 
(<0.1 %). 
 
3.2.6 Cancer cell viability upon exposure to carboplatin in free form, NT and 
FRT liposomes 
For the evaluation of anti-cancer activity of the various forms of carboplatin, 
the FR-overexpressing KB cells and the FR negative A549 cells were used.  A 
concentration-dependent decrease in the viability of KB cells (Figure 3.7) and A549 
cells (Figure 3.8) was observed when the cells were treated with carboplatin-loaded 
FRT and NT liposomes as well as with the free drug.  Drug-free liposomes did not 
show significant toxicity towards KB cells or A549 cells (viability > 98%).  As 
expected, the IC50 values of FRT liposomes were significantly lower than the IC50 
values of NT liposome and free drug in FR positive KB cells (p < 0.05).  Based on 
the cell viability data, the IC50 values for FRT carboplatin liposomes, NT carboplatin 
liposomes and free carboplatin in KB cells were estimated to be 7.16 ± 0.26 µM, 





Figure 3.7:  Viability of FR positive KB cells upon exposure to free carboplatin (●), 
NT liposome (♦), FRT liposome (■) and FRT liposomes in the presence of 1 mM 
folic acid (×) for 72 h.  Free carboplatin was in the form of solution in 0.9% w/v 
NaCl.  Data represent mean  S.E.M of five independent experiments.  At least three 
independent batches of NT and FRT liposomes were tested. Few error bars are too 
small to be seen. 
 
 
Table 3.2:  IC50 values of free carboplatin, NT and FRT liposomes on FR positive KB 
cells and FR negative A549 cells 
 
Cell Lines Free Carboplatin (µM) NT liposome (µM) FRT liposome (µM) 
KB cells 40.72±4.23a 29.37±3.77 7.16±0.26b 
A549 cells 174.87±2.64 170.90±2.94 167.10±2.77 
Cell viability was determined using MTT assay and subsequently analysed by 
Calcusyn 3.0 software to estimate IC50 values. Results shown are the mean ± S.E.M 
from at least three independent experiments. All r-values were > 0.9.  a p > 0.05 for 








Figure 3.8:  Viability of FR negative A549 cells upon exposure to free carboplatin 
(●), NT liposome (♦) and FRT liposome (■) for 72 h.  Free carboplatin was in the 
form of solution in 0.9% NaCl.  At least three independent batches of NT and FRT 
liposomes were tested on each cell line. Results shown are the mean ± S.E.M from at 
least three independent experiments. Some error bars are too small to be seen. 
 
This finding demonstrated enhancement in carboplatin potency by 5.7-fold as 
compared to free drug, and by 4.1-fold as compared to the NT liposomes in KB cells.  
Yet, no significant difference was observed in the IC50 values among FRT carboplatin 
liposomes (167.10 ± 2.77 µM), NT carboplatin liposomes (170.90 ± 2.94 µM) and 
free drug (174.87 ± 2.64 µM) when tested in the FR negative A549 cells (Table 3.2).  
These results suggest that FR overexpression plays an important role in the enhanced 
potency of carboplatin via FRT liposomal delivery.  To verify the role of FRME in 
enhanced cytotoxicity of FRT liposomes, KB cells were concurrently treated with 
FRT liposome and 1 mM free folic acid.  The IC50 values of FRT carboplatin 
liposomes significantly increased from 7.16 ± 0.26 µM to 48.43 ± 4.63 µM in 
presence of 1 mM free folic acid (Figure 3.7).  This indicated that the enhanced 
cytotoxicity of carboplatin in FRT liposomes was dependent on the differential 





3.2.7 Cellular uptake of fluorescent liposomes 
Cellular uptakes of FRT and NT liposomes encapsulating the fluorescent lipid 
DiI were determined in FR positive KB cells upon 4 h and 24 h of incubation.  As 
shown in Figure 3.9, FRT liposomes showed much greater cellular uptake and 
liposome internalisation compared to NT liposomes at 4 h.  This internalisation of 
fluorescent FRT liposomes was prevented in the presence of 1 mM free folic acid (C). 
Similar trends were obtained with longer incubation time whereby cellular uptake of 
liposomes was further increased (Figure 3.10).  Interaction of the FRT liposomes with 
FR could be prevented by folic acid.  The results corroborated with previous 
observations whereby FRME was proposed as a pathway of internalizing FRT 






Figure 3.9: Cellular uptake of FRT-DiI liposomes (A), NT-DiI liposomes (B) and 
FRT-DiI liposomes in presence of 1mM free folic acid (C) after treatment on KB cells 
for 4 h. Left panel represents micrographs taken in the phase-contrast mode whereas 
right panel shows the same field viewed in the fluorescence mode. Results shown are 





Figure 3.10: Cellular uptake of FRT-DiI liposomes (A), NT-DiI liposomes (B) and 
FRT-DiI liposomes in presence of 1mM free folic acid (C) after treatment on KB cells 
for 24 h. Left panel represents micrographs taken in the phase-contrast mode whereas 
right panel shows the same field viewed in the fluorescence mode. Results shown are 




3.2.8 Cellular platinum accumulation and DNA-Pt adduct formation  
Since FRT liposomes showed an FR dependent uptake in KB cells, it was 
anticipated that the enhanced cytotoxicity of the formulation was associated with an 
increased cellular Pt uptake.  Therefore, cellular Pt accumulation and consequently 
cellular DNA-Pt adduct formation were determined and compared among the various 
formulations of carboplatin. Figure 3.11A demonstrates significantly higher 
accumulation of Pt when treating the KB cells with the FRT liposomes as compared 
to the free drug and the NT liposomes (p < 0.05), with approximately 2-fold increase 
over the free drug and 4-fold increase over the NT liposomes.  In contrast, cellular Pt 
accumulation was not statistically different when comparing free drug, NT and FRT 
formulation in FR negative A549 cells (Figure 3.11B).  This suggested that increased 
cellular accumulation of Pt in KB cells upon treatment with FRT liposomal 
carboplatin was due to FR-mediated endocytosis.   
In light of this finding, it was anticipated that the formation of DNA-Pt 
adducts would be increased and correlated with the observed enhancement in 
carboplatin potency.  Therefore, our next step was to measure DNA-Pt adducts 
formed in the KB cells.  Platination of DNA by carboplatin is comparatively slower 
than cisplatin; therefore, a longer incubation time of 48 h was chosen for the 
experiment [197].  Surprisingly, the amount of DNA-Pt adducts formed from FRT 
carboplatin liposomes was significantly lower than that of the free drug (Figure 
3.11C).  These results suggest that the cytotoxicity of FRT carboplatin liposomes 
might be mediated through some other molecular targets in addition to the formation 




Figure 3.11:  Cellular Pt accumulation in FR positive KB cells (A), FR negative A549 
cells (B), and DNA-Pt adduct formation in KB cells (C) for free carboplatin, NT or 
FRT carboplatin liposomes.  Platinum content was analysed by AAS as described in 
method section.  Data represent mean  S.E.M of four independent experiments for 






3.2.9 Enhanced ERK activation by FRT liposomes  
As discussed in section 1.3.2, several studies have reported the role of ERK 
activation in cisplatin- and carboplatin-induced apoptosis [60-64, 198].  It was thus 
interesting to probe if ERK activation would be observed in KB cells upon exposure 
to FRT carboplatin liposomes, which in turn, mediated the cytotoxic effect of these 
liposomes.  In general, treatment with carboplatin in the three different forms resulted 
in significantly higher levels of phosphorylated ERK (p-ERK) as compared to control 
(p < 0.05, Figure 3.12).  Among the three formulations of carboplatin, densitometry 
analysis showed that FRT carboplatin liposomes displayed the highest level of p-ERK 
activation, which was significantly higher than free carboplatin and NT carboplatin 
liposomes (p < 0.05).   
 
 
Figure 3.12:  Phosphorylation of ERK in KB cells treated with free carboplatin, NT 
and FRT liposomes with or without drug encapsulation.  -actin was used as the 
loading control.  Representative blots from three independent experiments are shown. 
Folds of ERK activation were calculated from the relative intensity of the bands 





Of note, ERK activation was also noticed in drug-free FRT liposomes, which 
warranted further investigation.  Hence, ERK activation was probed in KB cells 
treated with increasing concentration of non-drug loaded FRT liposomes.  As seen in 
Figure 3.13, concentration dependent ERK activation could be observed when KB 
cells are treated with 1.25 mM, 2.5 mM, 5 mM and 10 mM (lipid concentration) of 
FRT liposomes.  This observation might shed new light on the utility of these targeted 
systems in modulating cell survival signalling pathways.  
 
 
Figure 3.13:  Phosphorylation of ERK in KB cells when treated with increasing 
concentration of empty FRT liposome. -actin was used as the loading control.  
Representative blots from three independent experiments are shown 
 
To confirm whether ERK activation played a significant role in carboplatin 
loaded FRT liposome induced cell death, KB cells were treated with increasing 
concentrations of carboplatin FRT liposomes.  Cells were also concurrently treated 
with 250 µM of carboplatin (FRT liposome) in the presence of selective MEK/ERK 
inhibitors, U0126 or PD98059.  Figure 3.14 showed a concentration-dependent 
activation of ERK upon treatment with carboplatin FRT liposomes, which could be 
inhibited by concurrent treatment with either of the ERK inhibitors.   
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Figure 3.14:  Phosphorylation of ERK in KB cells treated with increasing 
concentrations of FRT carboplatin liposomes and in presence of ERK inhibitor U0126 
and PD98095.  -actin was used as the loading control.  Representative blots from 
three independent experiments are shown. 
 
3.2.10 Cell viability assay in presence of ERK inhibitors 
To corroborate the finding on ERK activation, MTT assay was performed on 
KB cells treated with carboplatin FRT liposomes, NT liposomes and free drug in 
presence or absence of these two MEK/ERK inhibitors.  In general, significant 
increase in cell viability could be observed when the drug-treated cells were incubated 
with the MEK/ERK inhibitors U0126 (Figure 3.15A) and PD98059 (Figure 3.15A) 
for the three forms of carboplatin.  The % relative increase in the viable cell fraction 
upon ERK inhibition, as calculated by the equation in section 2.4., was determined 
and compared among carboplatin loaded FRT liposomes, NT liposomes and free 
carboplatin to delineate the contribution of ERK activation in mediating the cytotoxic 
effect.  As shown in Figure 3.16, FRT carboplatin liposomes displayed the highest 
increase in viable cell fraction upon ERK inhibition by U0126 and PD98059, which 
was significantly different from the free drug and NT carboplatin liposomes (p < 




mediating the cytotoxicity of FRT carboplatin liposomes rather than DNA-Pt adduct 
formation.   
 
Figure 3.15:  Percentage cell viability of KB cells upon exposure to 80 µM of free 
carboplatin, 80 µM of NT liposome and 60 µM of FRT liposome for 72 h in presence 
(dark coloured bars) or absence (light coloured bars) of Erk inhibitors U0126 (A) and 
PD98095 (B).  Free carboplatin was in the form of solution in 0.9% w/v NaCl.  Five 
independent batches of both NT and FRT liposomes were tested on each cell line.  





Figure 3.16:  Percent relative increase in viable cell fraction of free carboplatin 
(white), carboplatin loaded NT (grey) and FRT liposomes (black) in treated KB cells 
with or without U0126 (10 µM) and PD98095 (20 µM).  Results shown are the mean 
± S.E.M from at least three independent experiments.   
 
3.3. Discussion  
Increased tumour drug accumulation by liposomal delivery does not 
necessarily translate to optimal therapeutic activity.  This is illustrated by SPI-077, the 
PEGylated liposomal cisplatin formulation, which exhibited poor drug release from 
the liposome carrier resulting in negligible therapeutic activity in patients [184, 185, 
192, 199].  A strategy to resolve this issue is the development of liposomes responsive 
to triggering mechanisms to promote release of the encapsulated content, and a 
thermosensitive liposomal formulation of cisplatin has been described previously 
[181].  Alternatively, targeted intracellular delivery of liposomally encapsulated 
content to cancer cells could allow the drug content to be delivered directly to the 
target population that is based on a different mode of drug entry into the cells.  In this 




their cytotoxicities in FR overexpressing KB cancer cells, with the anticipation that 
FR-mediated endocytosis of FRT liposomes would increase cellular accumulation of 
carboplatin, which in turn, would enhance the formation of DNA-Pt adducts and 
subsequent cytotoxicity.  Several important observations could be made and discussed 
as follows. 
From a formulation perspective, the first objective was to develop a 
carboplatin loaded FRT liposome with different lipid compositions in order to get 
optimumal drug loading.  The results obtained were promising as the D/L ratio 
achieved in DPPC-NT (0.062 ± 0.004) and DPPC-FRT (0.057 ± 0.006) formulation of 
carboplatin were higher than the D/L (w/w) ratio of Stealth® liposome (SPI-077) 
formulation of cisplatin (0.014)  as well as that of the thermosensitive liposomal 
formulation of cisplatin (0.018) [181, 185, 192].  This higher drug loading capacities 
of both NT and FRT liposomes could be attributed to the high external concentration 
(initial D/L ratio of 0.25:1) of carboplatin which may have facilitated the entry of this 
hydrophilic molecule into the liposomal core [191].  Carboplatin loaded NT and FRT 
liposome formulations exhibited similar drug release profiles as shown in Figure 3.5, 
and this finding demonstrates that the folate ligand did not substantially interfere with 
the release of carboplatin from the FRT liposomes.  Both the formulations had size in 
the preferred nano-range which was also confirmed by Cryo-TEM studies.  Taken 
together, the optimised formulation indicated the successful encapsulation of 
carboplatin in FRT liposomes. 
From a therapeutic perspective, the significant improvement in potency (Table 
3.2) of the carboplatin loaded FRT formulation demonstrated the therapeutic 
advantage of the formulation over the NT liposomes and free drug.  Moreover, the 




not confer enhancement in carboplatin potency when the cancer cells had negligible 
FR expression.  Thus, the improved potency could be attributed to the effective 
internalisation of carboplatin into the FR overexpressing KB cells through FRT 
liposomal delivery.  This also confirmed by efficient cellular uptake of fluorescent 
liposomes, which was reversed in presence of free folic acid.  Of note, the increased 
cellular accumulation of carboplatin in KB cells by FRT liposomal delivery could not 
be attributed to a difference in the drug release of the NT and FRT liposomes as drug 
release from both the liposomes was almost similar.  Indeed, our current data on FRT 
carboplatin liposomes are in agreement with previous studies involving FRT 
liposomal delivery of doxorubicin, paclitaxel, docetaxel and 5-FU that conferred 2-3 
fold improvement in IC50 values when compared to the free drug [123, 156, 159, 164].  
However, in contrast to our expectation, the increased cellular accumulation of 
carboplatin by FRT liposomal delivery did not correlate with increased formation of 
DNA-Pt adducts.  From our data, carboplatin in free form had higher levels of DNA-
Pt adduct formation as compared to FRT liposomes.  Pt-based compounds in their free 
form are reported to act primarily through DNA-Pt adduct formation; thus, it is 
intriguing to observe a discrepancy between carboplatin potency and DNA-Pt adduct 
formation in our current study.  Aronov et al have described similar findings with 
folate-PEG conjugated carboplatin analogues, supported by data from cellular 
accumulation of Pt and confocal microscopy [95].  In their study, the IC50 values of 
the analogues did not correlate with cellular Pt accumulation or DNA-Pt adduct 
formation.  Thus far, no further studies have been performed to address this 
discrepancy.  It was thus our intention to investigate into this observation, and for the 




liposomal delivery could be associated with other molecular targets in addition to 
DNA-Pt adduct formation. 
Recently, the anti-cancer mechanisms of Pt-based compounds have been 
described to involve more complex cellular and molecular events in addition to the 
formation of DNA-Pt adducts.  Several research groups have reported the active role 
of ERK in mediating the cytotoxicity of cisplatin and carboplatin.  These studies have 
provided the basis for us to probe ERK activation as a molecular event in mediating 
the cytotoxic effect of carboplatin delivered via FRT liposomes [60-64, 198].  Our 
results demonstrated significantly higher ERK activation by FRT carboplatin 
liposomes as compared to free form and NT liposomes.  This effect could be observed 
in drug free FRT liposomes at 10mM lipid concentration.  ERK activation upon 
treatment with carboplatin FRT liposomes was concentration-dependent, and could be 
reversed in the presence of MEK/ERK inhibitors.  Furthermore, the concurrent use of 
MEK/ERK inhibitors produced the greatest % relative increase in viable cell fraction 
in the FRT carboplatin liposome group.  Collectively, these findings suggest that 
different routes of drug entry could lead to potential shift in the intracellular 
distribution of carboplatin and its mechanism of action, whereby DNA-Pt adduct 
formation may not remain as the primary molecular target of carboplatin when 
delivered in the FRT liposome.  Figure 3.17 presents the comparison of carboplatin 
delivered as free form or in FRT liposomes, with ERK activation proposed to be the 





Figure 3.17:  Comparison of the mechanism of action of carboplatin delivered in free 




Our studies showed that carboplatin could be successfully loaded into FRT 
liposomes with better D/L ratio than liposomal cisplatin formulation SPI-077 and 
thermosensitive cisplatin liposomes.  The liposomes showed sustained drug release 
and size within 100 nm.  Potency of carboplatin was significantly enhanced when 
delivered by FRT liposomes in FR overexpressing KB cells.  Results showed that 
enhanced cytotoxicity was atributed to efficient internalisation through FR and could 
be blocked with free folic acid.  For the first time, enhanced cytotoxicity of FRT 
carboplatin liposomes could be related to increase cellular Pt-uptake and ERK 






EVALUATION OF IN VIVO THERAPEUTIC ACTIVITY IN 
HUMAN OVARIAN CANCER XENOGRAFT MODEL 
 
4.1. Introduction 
As mentioned in section 1.3.3, poor prognosis and fewer treatment options 
make advanced ovarian cancer difficult to treat.  Recent clinical trials have shed light 
on the usefulness of intraperitoneal chemotherapy to extent the overall survival of 
patients [30, 200-202].  As mentioned before, i.p. therapy provides a high loco-
regional concentration of the drug and a longer half-life of the drug in the peritoneal 
cavity compared to i.v. route, which in return helps to eradicate the neoplastic cells 
after tumour debulking [33].  In addition, according to NCI, administration through i.p 
route also provides a longer systemic exposure to the anticancer drugs [33].  Since 
carboplatin is widely used as a first line treatment of ovarian cancer, i.p therapy of 
carboplatin may provide therapeutic benefit to patients.  Several on-going clinical 
trials are investigating the potential benefit of this route for carboplatin [39, 42].  
However, similar to cisplatin, carboplatin also shows poor absorption rates in solid 
tumours [20, 70].  To obviate this problem, FRT liposomes could be used as the 
enabling technology to deliver carboplatin into ovarian cancer cells.   
In this chapter, the previously developed carboplatin loaded FRT liposomes 
were tested for its efficacy in an FR positive human ovarian cancer model.  Several 
ovarian cancer cell lines were screened for the overexpression of FR, among which 




fluorescent liposomes and Pt-cellular uptake studies were performed to evaluate the in 
vitro therapeutic benefit of the FRT formulation in the ovarian cancer setting.  
Intraperitoneally growing IGROV1 cells were used as an established ovarian cancer 
xenograft model which closely mimic clinically growing ovarian cancer while over 
expressing the FR [203, 204]. 
 
4.2 Results  
4.2.1 Determination of FR expression of ovarian cancer cells by flow cytometry  
As a start, several ovarian cancer cell lines were tested for overexpression of 
FR.  As seen in Figure 4.1, IGROV1 ovarian cancer cell lines showed amplified FR 
expression (> 90%) which was comparable to the gold-standard KB cells.  However, 
SKOV3 (< 2 %) and OVCAR-3 (< 1 %) were devoid of the FR.  
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Figure 4.1:  FR expression in ovarian cancer cells lines IGROV1 (A), SKOV3 (B) and 
OVCAR-3 (C).  The control panel represents cells without incubation with primary 
antibody.  Results shown are representative profiles from at least three independent 
experiments. 
 
4.2.2 Cancer cell viability upon exposure to carboplatin in free form, NT and 
FRT liposomes 
IGROV1 cells on treatment with increasing concentrations of free carboplatin, 
and carboplatin loaded NT and FRT liposomes, showed a concentration dependent 
cellular growth inhibition (Figure 4.2).  Drug-free NT liposomes and FRT liposomes 




3.4% and 99.07 ± 0.3%, respectively.  Based on the cell viability data, the IC50 values 
for FRT carboplatin liposomes, NT carboplatin liposomes and free carboplatin in 
IGROV1 cells were 13.09 ± 0.63 μM, 40.1 ± 4.95 μM and 24.02 ± 1.56 μM, 
respectively.  The values obtained indicated that FRT liposomes were significantly 
effective in suppressing the tumour cell viability when compared to both the free drug 
and drug loaded NT liposomes (p < 0.05).  In accordance to previous observation, 
presence of 1 mM free folic acid could block the FRME process, whereby IC50 value 
of FRT liposomes in presence of folic acid is significantly increased when compared 
to FRT liposomes in absence of free folic acid (Table 4.1).  
 
 
Figure 4.2:  Viability of FR positive IGROV1 cells upon exposure to free carboplatin 
(●), NT liposome (♦), FRT liposome (■) and FRT liposomes in presence of 1mM 
folic acid (×) for 72 h.  Free carboplatin was in the form of solution in 0.9% w/v 
NaCl.  Data represent mean  S.E.M of five independent experiments.  At least three 
independent batches of NT and FRT liposomes were tested.  Few error bars are too 







Table 4.1:  IC50 values of free carboplatin, NT and FRT liposomes on IGROV1 cells 
Groups IC50 values (µM) 
Free Carboplatin  24.02±1.56a, b 
NT liposome  40.1±4.95 a, b 
FRT liposome  13.09±0.63b,c 
FRT liposome + 1mM free folic acid 28.96±5.29c 
Cell viability was determined using MTT assay and subsequently analysed by 
Calcusyn 3.0 software to estimate IC50 values.  Results shown are the mean ± S.E.M 
from at least three independent experiments.  All r-values were > 0.9.  a p < 0.05 for 
free form vs NT liposomes; b p < 0.05 for FRT liposomes vs free form and NT 
liposomes; c p < 0.05 for FRT liposomes in presence of 1 mM free folic acid vs FRT 
liposomes. 
 
4.2.3 Cellular uptake of fluorescent liposomes 
Cellular uptake of FRT and NT liposome encapsulating a fluorescent lipid DiI 
was determined in FR positive IGROV1 cells to confirm the previous observation 
with KB cells.  As shown in Figure 4.3 and 4.4, FRT liposomes showed much greater 
cellular uptake and liposome internalisation compared to NT liposome at 4 h and 24 
h, respectively.  This observation was similar to the observations with KB cells as 
internalisation of fluorescent FRT liposomes was prevented in presence of 1 mM free 
folic acid.  With longer incubation, higher levels of accumulation of the FRT 






Figure 4.3:  Cellular uptake of FRT-DiI liposomes (A), NT-DiI liposomes (B) and 
FRT-DiI liposomes in presence of 1mM free folic acid (C) after treatment on 
IGROV1 cells for 4 h.  Left panel represents micrographs taken in the phase-contrast 
mode whereas right panel shows the same field viewed in the fluorescence mode.  






Figure 4.4:  Cellular uptake of FRT-DiI liposomes (A), NT-DiI liposomes (B) and 
FRT-DiI liposomes in presence of 1mM free folic acid (C) after treatment on 
IGROV1 cells for 24 h.  Left panel represents micrographs taken in the phase-contrast 
mode whereas right panel shows the same field viewed in the fluorescence mode.  
Results shown are representative from at least three independent experiments. 
 
4.2.4 Cellular platinum accumulation  
To affirm whether the enhancement in cytotoxic effects of the targeted 
formulation was due to increased cellular uptake, Pt concentrations in IGROV1 cells 
were measured.  Figure 4.5 demonstrates that Pt uptake in FRT liposome treated 




liposome treated cells.  Pt uptake in FRT liposomes treated cells were almost two fold 
higher than the other groups and this may have contributed to the enhanced 
therapeutic effect of the same.  This observation was also in accordance to the results 
obtained on KB cells.  
 
 
Figure 4.5  Cellular Pt accumulation of carboplatin in IGROV1 cells delivered as free 
form, NT or FRT liposomes.  Data represent mean  S.E.M of three independent 
experiments for cellular accumulation study.  At least three independent batches of 
NT and FRT liposomes were tested. 
 
4.2.5 In vivo anti-tumour efficacy 
The therapeutic efficacy of FRT carboplatin liposomal formulation was 
compared to the free drug and carboplatin loaded NT liposomes, whereas saline 
treated group was used as the control group without treatment.  As shown in Figure 
4.6, mice in all other groups died within 19-39 days post tumour cell inoculation, 




survival rate of 83%.  The median survival time (MST) for saline control, free drug 
and NT liposome treated group were 26.5, 26, and 28.5 days, respectively (Table 4.2).  
On the other hand, 5/6 FRT liposome treated animals survived till 60 days after 
tumour cell inoculation.  Log rank test indicated statistically significant difference 
between FRT liposome treated group in comparison to saline control, free drug, and 
NT liposome (p < 0.01). 
 
 
Figure 4.6:  Kaplan-Meier survival curves of the different treatment groups over time.  
Mice were inoculated intraperitoneally with 5 X 106 human IGROV1 FR positive 
ovarian cancer cells and were treated (six per group) intraperitoneally with saline 
(blue), free carboplatin (green), carboplatin loaded NT liposomes (red) and FRT 
liposomes (black).  Animal survival was recorded from the day of tumour cell 





Table 4.2:  In vivo efficacy of localised carboplatin treatment given in various formulations in the IGROV1 human ovarian tumour 
intra-peritoneal xenograft model. 
 
Study group Median survival time (MST)a
(days) 
Survival time 
(Range in days) 
Long term 
survivors (LTS)b  
Percentage weight change at 
nadirc 
Saline control 26.5 19-33 0/6 -4.11 ± 1.65 
Free carboplatin 26 21-39 0/6 9.3 ± 7.6 
NT liposome 28.5 15-36 0/6 20.47 ± 10.42 
FRT liposome NA 43-LTS 5/6 7.96 ± 1.44 
ap < 0.01, log rank test.  Carboplatin was injected as free drug or liposomal formulation (NT or FRT) at a dose of 15 mg/kg as a 
single i.p. injection on day 14, 18, 21, 25, 28 and 32 post tumour inoculation.  bLong term survivors are defined as mice surviving 
till the end of the experiment  which was 60 days from the time of inoculation of the cancer cells.  cPercentage weight change at 





4.2.6 Assessment of carboplatin concentration in systemic circulation  
Platinum concentration in blood was estimated after 24 h of weekly dosing in 
order to estimate the level of carboplatin in systemic circulation.  As depicted in 
Figure 4.7, carboplatin concentration in plasma upon treatment with NT and FRT 
liposome was lower after weekly dosing.  Though not significantly different from 
FRT and NT liposomes, free drug concentration could also be detected in the plasma 
after 24 h of treatment with dose 1-2 and 3-4 (~1 mg/L).   
 
 
Figure 4.7:  Concentration of carboplatin in plasma of SCID mice after i.p. 
administration of free carboplatin and carboplatin loaded NT liposomes and FRT 
liposomes at a dose of 15 mg/kg for single injection.  Carboplatin was administered 
for a total of six doses where the blue, red and green bar represents dose 1-2, 3-4 and 
5-6, respectively.  Results shown are the mean ± S.E.M values obtained from at least 
three mice except in dose 5-6 where, n = 2 and n = 1 for free drug and NT liposome 
treated groups, respectively. 
 
Previous studies by Pan et al have shown that i.p administration of DOX 
encapsulated in FRT liposomes and NT liposomes led to longer circulation life time 
in comparison to free DOX [154].  Presence of PEG layering on both DOX loaded 
FRT liposomes and NT liposomes was cited as the plausible reason behind the 




accordance to the previous findings by Pan et al. PEGylation of liposomes may have 
resulted in longer circulation of carboplatin loaded FRT and NT liposomes which was 
reflected by the higher plasma concentrations of the formulations compared to free 
carboplatin.  
 
4.2.7 Toxicity assessment from change in body weight and spleen weight  
Change in body weight is considered as an indicator for drug induced toxicity, 
disease progression and is also often considered as the critical parameter to determine 
the maximum tolerated dose (MTD) of the drug.  In this study, the chosen dose of 
carboplatin (15 mg/kg) was much lower than its MTD (in mice) due to the localised 
treatment and targeted drug delivery approach [205, 206].  Therefore, an acute weight 
loss due to chemotherapy could not be observed in any of the treated groups during 
chemotherapy (Figure 4.8A).  However, the % weight change at nadir for the NT 
liposome group was found to be about 20% though it was not statistically different 
from the other groups.  Instead of weight loss, the saline control group demonstrated 
an increase in body weight initially which could be due to the growing tumour mass 
and ascites fluid.  It is noteworthy that FRT liposome treated group did not show any 
significant change in weight (p>0.05) before, after or during chemotherapy.  In 
addition, the normal mice (without tumour) demonstrated an insignificant weight gain 
during the course of the study.  
Other than change in weight, increase in spleen weight was also monitored as 
an indicator of potential toxicity.  Increase in spleen weight is often clinically 
associated with various pathological factors such as presence of acute infection or 
disease such as leukemia, lymphomas, acute anaemia, malaria, leishmaniasis, solid 




chemotherapy with Pt compound oxaliplatin [208].  In this study, we determined the 
change in spleen size by measuring its weight, upon sacrificing the animals during the 
efficacy study.  As shown in Figure 4.8B, significant increase in spleen weight was 
observed for mice treated with saline, free drug or NT liposomes when compared to 
both the FRT treated group and normal mice (without tumour inoculation).  
Approximately 2 to 3 fold increase in spleen weight was observed among these three 
groups.  Progression of the disease may have led to an enlarged spleen as presence of 
solid tumours and lymphomas has long been associated with this condition [207].  In 
addition, bigger spleen of the free drug and NT liposome treated groups could be 
attributed to the enhanced toxic effects of the drug due to localised treatment [208].  
In contrary, the FRT treated group did not show any such changes in spleen weight 
when compared to normal mice, possibly due to the eradication of the tumour or the 
alleviation of the diseased state or could be due to the reduction in toxicity from FRT 




Figure 4.8:  (A) Changes in body weight and (B) dry weight of spleen (g) normalised 
to the body weight of mice (g) after tumour cell inoculation and treatment with 
intraperitoneally administered saline (♦, 1), free carboplatin (■, 2), NT liposome (▲, 
3), FRT liposome (•, 4) or mice without tumour cell inoculation (×, 5).  Body weights 
were measured at-least three times per week, where arrows indicate days of 
chemotherapy.  Spleen was excised from dead mice.  Results shown are the mean ± 
S.E.M values obtained from at least three mice.  *p < 0.05 for FRT liposome treated 
mice vs. all groups except without tumour cell inoculation.  **p < 0.05 for mice 
without tumour cell inoculation vs. all groups except FRT.  
 
4.2.8 Histopathological evaluation of mice tissues  
None of the treatment group showed any signs of drug induced toxicity as 
observed from the H & E stained tissues of lungs, liver and kidneys.  The tissues 




was observed.  Though carboplatin is not significantly nephrotoxic than its parent 
compound cisplatin [46], it was still important to investigate whether any 
histopathological alteration were caused in the renal tissues by the drug loaded 
formulation.  As expected, there were no signs of tubular degeneration or necrosis of 
the renal tissues (Figure 4.10, 4.11 and 4.12).   
Due to lack of effective diagnostic test and early clinical symptoms, ovarian 
cancer is detected mostly at an advance stage where the cancer has spread through the 
lymphatic system to the lymph nodes into the pelvis, abdomen or lungs [10, 209].  
This phenomemon is evident from Figure 4.9 which shows a mediastinal lymph node 
filled with neoplastic cells from untreated mice (saline control).  Similar observations 
could be made in mice treated with free carboplatin and NT liposome.  In contrast, 
mice from FRT liposome treatment group that survived the study period did not show 
the spreading of neoplastic cells through the lymph nodes.   
 
 
Figure 4.9:  Histopathological evaluation of excised tissue indicating presence of 
cancer cells in mediastinal lymph node of saline control.  Arrow indicates presence of 





As a result of such migration, neoplastic cells can invade the major organs 
such as liver and lungs [209, 210].  The H & E stained slides were also indicative of 
such metastasis caused by the progression of the cancer.  As shown in Figure 4.10, 
substantial metastasis of the cancer cells were observed in lungs obtained from saline 
control group, free drug treated and NT liposome treated group.  Neoplastic cells were 
found within the capillary of the lungs.  Both clumps and individual neoplastic cells 
were observed in lung lobes of saline-control mice, free drug treated mice and drug-
loaded NT liposomes treated mice (Figure 4.10).  In contrast, metastasis could not be 
observed in long term survivors of FRT treated mice.  This suggests that the FRT 
formulation was effective in preventing metastasis of the ovarian cancer cells.  
 
Figure 4.10:  Histopathological evaluation of excised tissue indicating presence of 
cancer cells in lungs of saline control (A), free carboplatin (B) and NT liposome (C) 
treated mice.  Mice from FRT liposome treatment (D) group that survived the study 
period did not show any metastasis.  Arrow indicates presence of cancer cells. 





Cancer cells were also found on the surface of the renal tissues and liver 
capsule of all treated mice except the long term survivors.  Clusters of neoplastic cells 
could be found in between the liver capsule and the wall of the gall bladder in all mice 
which died of tumour burden (Figure 4.11).   
 
 
Figure 4.11:  Histopathological evaluation of excised tissue indicating presence of 
cancer cells on the outer surface of liver capsule in saline control (A), free carboplatin 
(B) and NT liposome (C) treated mice.  Mice from FRT liposome treatment (D) group 
that survived the study period did not such presence.  Arrow indicates the presence of 
cancer cells. Representative images of liver metastasis have been shown.  
 
Similarly, neoplastic cells were observed in the peritoneum covering the 
kidney (Figure 4.12).  This was expected because the neoplastic cells were injected 
into the peritoneal cavity and would be able to readily "seed" onto the surface of the 
kidney, which is always partially covered by the peritoneum.  However, to be a true 




and bloodstream and arrive in the kidney via the arteriole blood and then create 
neoplastic masses in the substance of the kidney.  No animals had this in the sections 
examined.   
 
 
Figure 4.12: Histopathological evaluation of excised kidney showing normal cellular 
morphology and presence of cancer cells on its outer surface in saline control (A).  
Mice from FRT liposome treatment (B) group that survived the study period did not 
indicate such presence.  Arrow indicates the presence of cancer cells. Representative 
images of kidney metastasis have been shown.  
 
4.3. Discussion  
Cellular Pt uptake studies on IGROV1 cells demonstrated a two-fold greater 
uptake of carboplatin when delivered through FRT liposome in comparison to both 
the free drug and NT liposomes.  The significant difference in IC50 values of FRT 
liposome in comparison to the free drug and NT liposome reflected the improved 
efficacy of our targeted system yet in another FR positive cell line.  Therefore, the 
next goal was to determine the in vivo therapeutic efficacy of FRT liposomal 
carboplatin in human xenograft ovarian cancer model.  The intraperitoneally growing 
FR positive IGROV1 ovarian cancer model was chosen to mimic the clinical nature of 
tumour burden in women with advanced stage ovarian cancer [211].  Superior 
survival rates were obtained when SCID mice were intraperitoneally treated with 




and NT liposome treated group died of tumour burden within 19-39 days post tumour 
cell inoculation, only one out of six mice in FRT group on the 43rd day.  It should be 
noted that mice from saline treated, free drug treated and NT liposome treated groups 
had similar MST, whereas; MST of FRT liposome treated group could not be 
calculated due to 5/6 LTS.  This indicated strong therapeutic benefit (p < 0.01) over 
all other treatment groups, and was in accordance to results obtained by Pan et al in 
KB oral carcinoma murine xenograft model which showed statistically significant 
difference in survival rates when FRT DOX liposomes were compared with NT DOX 
liposomes and free DOX given intravenously [154].  However, it should be noted that 
the tumour model and route of administration (i.v.) of DOX was different from our 
present study.  Previous studies with transferrin conjugated pegylated liposomal 
formulation of cisplatin did not confer superior survival rates when compared to drug 
loaded NT pegylated liposomes after i.p. administration for the treatment of  gastric 
cancer [212].  However, both these formulations could prolong the survival rates in 
mice when compared to mice treated with free drug and PBS.  It was proposed that 
both these formulations may have sufficiently accumulated in the tumour site by EPR 
effect due to prolonged residence time in the peritoneal cavity and longer circulation 
lifetime.  Collectively, results from our in vitro and in vivo studies suggested that FRT 
liposomal carboplatin was delivered into FR overexpressing tumour cells by FRME 
that mediates the therapeutic benefit [213, 214].  This observation is supported by a 
study which demonstrated enhanced uptake of FRT liposomes (non-drug loaded) in 
IGROV1 cells and tumour associated  macrophages of mice bearing intraperitoneally 
grown IGROV1 cells [204]. 
Moreover, histopathological evaluation of excised lung, liver and kidney 




presence of neoplastic cells in lungs, whereas tissues from LTS of FRT liposome 
treated group did not show any signs of such metastasis.  However, the FRT 
liposomes treated mouse that died of tumour burden also showed signs of metastasis.  
In this regard, it should be noted that NCI has classified ovarian cancer into four 
different stages, where stage IV clinically relates to metastasis of ovarian cancer cells 
outside the abdomen and pelvis, in the lungs, liver, and other organs of the body 
[215].  Our findings indicate that carboplatin loaded FRT liposomes were not only 
able to cure or reduce the intraperitoneally growing tumour but may have been 
additionally effective in eradicating tissue metastasis in most of the animals.  This 
additional therapeutic benefit of the FRT liposome may have resulted from the 
presence of the drug in systemic circulation, even after 24 h of local administration. 
Intraperitoneally administered drugs have shown to remain as a drug-depot to 
eradicate cancer cells systemically [183, 216].  Concentration of carboplatin in 
systemic circulation from FRT liposomes and NT liposomes was about ~2 mg/L 
whereas for free drug was about ~1 mg/L after 24 h of administration.  This dose is 
equivalent to ~5.39 µM for FRT and NT liposomes and ~2.69 µM for free 
carboplatin.  When referred back to the IC50 values of the formulations and free drug 
from in vitro cytotoxicity studies in IGROV1 cells (Table 4.1), it could be noted that 
the respective plasma concentration was only 2.4 times lower than the IC50 values of 
FRT liposomes, whereas more than 8-10 times lower when compared to IC50 values of 
NT liposomes or free carboplatin.  Since the FRT formulation was effective in 
reducing or may be eradicating intraperitoneally growing tumour, the remaining drug 
in plasma may have facilitated eradication of the metastasised cells, if any.  On the 
contrary, poor tumour uptake of NT liposomes and free carboplatin may have resulted 




concentration of drug from NT liposomes and free drug could not provide any 
additional therapeutic benefit for eradication of the metastasised cells.  
The improved therapeutic benefit of the FRT liposomes could be attributed 
to lower administered dose than the maximum tolerated dose (MTD) of carboplatin in 
mice.  The reported MTD of carboplatin in mice for i.p administration is ~150 mg/kg 
[205, 206].  Therefore both the free drug and formulated drugs were expected to be 
non-toxic to the mice.  Nevertheless, to further re-confirm this fact, toxicities studies 
were performed to analyse the toxic effects of both FRT and NT formulation and the 
free drug.  For this, change in body weight and change in spleen weight with respect 
of body weight was monitored and the histopathology of lungs, liver and kidneys 
were performed.  None of the treatment groups showed significant weight loss during 
the course of the study, wherein the FRT liposome treated group showed the lowest 
percentage weight change at nadir.  However, significant increase in dry spleen 
weight was observed in saline treated, free drug, and NT liposome treated group when 
compared to FRT liposomes or normal mice.  As discussed previously, this increase 
in spleen weight could be due to progression of the diseased state or toxic effects of 
the free drug, which was lacking for carboplatin encapsulated in FRT liposome [207, 
208].  In addition, H& E stained slides did not show any signs of drug induced tissue 
damage (lungs, liver, kidney) in any of the treated groups.  Of note, the current 
administered dose in mice (15 mg/kg) is equivalent to a dose of 45 mg/m2 in human, 
which is significantly lower than the recommended dose of 400 mg/m2 (q4w) in 
previously untreated adult patients [18, 46].  The results suggest that FRT liposomes 
could be administered to ovarian cancer patients at a lower dose than recommended 






Our studies have demonstrated potential in vitro and in vivo therapeutic efficacies of 
carboplatin in FR positive ovarian cancer.  This increased activity is supposed to be 
due to intracellular delivery of the drug through FRs.  Significant survival rates were 
achieved in female mice without signs of potential toxicity.  Our results suggest that 
FRT liposomal carboplatin has the potential to be developed as a clinical agent for the 






INVESTIGATION ON THE LYOPHILISATION OF LIPOSOMES 
FOR LONG TERM STORAGE  
 
5.1. Introduction 
So far, the thesis was successful in showing the potential of carboplatin loaded 
FRT liposomes for the treatment of ovarian cancer.  However, to be developed as a 
clinical agent, one of the most important aspects of any drug delivery system is the 
long-term stability of the product.  Lyophilisation or freeze-drying is a viable 
approach to improve the stability of the liposomes.  It has been reported that freeze-
drying or lyophilisation of liposomes can prevent hydrolysis of the phospholipids and 
physical degradation of the vesicles during storage [150].  However, lyophilisation of 
liposomes may induce physical changes by alterations in vesicle size and loss of the 
encapsulated agent [217].  It has been found that addition of cryoprotectants such as 
sucrose, glucose, trehalose, maltose, or lactose prevents leakage of hydrophobic drugs 
or fusion of liposomes [218-221].  Thus far, extensive studies have been performed on 
lyophilisation of cholesterol based liposomal systems, and also of pure DPPC [119, 
217, 220-223].  However, to the best of our knowledge, previous studies have not 
investigated the lyophilisation of cholesterol free PEGylated liposomes (CF-PEG) 
such as the NT and FRT liposomes in this thesis.  Furthermore, the  optimal 
cryoprotectant types and ratio to be used in a liposome system are  variable and is 
dependent on liposomal bilayer composition [224].  Hence, it is interesting to 




improve the stability of the NT and FRT liposomes.  Moreover, it may also help to fill 
in some of the existing knowledge gaps, about selection of cryoprotectants for 
cholesterol free PEGylated liposome systems and their overall effects on pertinent 
formulation characteristics are still unknown.  
 
5.2 Results  
5.2.1 Stability of NT and FRT liposomes loaded with carboplatin 
Retention of liposome encapsulating hydrophilic drugs upon long term storage 
has remained a major challenge in the field of liposomal drug delivery system.  Here, 
we investigated the long term stability of carboplatin loaded NT and FRT liposomes 
on storage at 4 ± 2º C for 300 days.  As illustrated by Figure 5.1A, both NT (> 30%) 
and FRT (> 20%) liposomes formulations showed significant decrease in drug content 
within one month of storage (p < 0.05), following slower drug leakage over the next 
300 days (20-65%).  However, as shown in Figure 5.1B and 5.1C, there were no 
significant change in the size and PI of both NT and FRT liposomes over this 300 day 
period (p > 0.05). 
Based on these observations, lyophilisation of NT and FRT liposomes were 
employed to improve the long term stability of the liposomes.  The initial 
investigation was carried out with NT liposomes to identify suitable cryoprotectant 
type, ratio and drug loading conditions.  Additionally, some other types of CF-PEG 
liposomes were also investigated to comprehend the effect of lyophilisation on 






Figure 5.1: Stability of Stability of NT (♦) and FRT (■) liposomes for a period of 300 
days on storage at 4 ± 2ºC.  Changes in drug content (A), size (B) and PI (C) was 
evaluated.  Results shown are the mean ± S.E.M from at least three independent 
batches of liposome formulation.   
 
5.2.2 Effect of cryoprotectants on lyophilisation of NT liposome and different 
CF-PEG liposomes 
Liposomes lyophilised without cryoprotectant showed a ten-fold increase in PI 
and more than a ten-fold increase in size (Figure 5.2).  Therefore, it was necessary to 
add cryoprotectants to protect the CF-PEG liposomes from fusion during 
lyophilisation.  Based on the literature available, three common cryoprotectants were 
identified for the lyophilisation of NT liposomes (DPPC/DSPE-PEG1000) and two 
other types of CF-PEG liposomes (DPPC/DSPE-PEG2000 or DSPC/DSPE-PEG1000) as 
shown in Table 5.1.  The effect of lyophilisation on the size and PI of different CF-
PEG liposomes were evaluated by adding sucrose, glucose or trehalose at different 






Figure 5.2: Size (A) and PI (B) of NT liposomes before and after lyophilisation 
without cryoprotectant.  Results shown are the average values ± S.E.M obtained from 











Sugar-to-lipid Before Lyophilisation Sucrose Trehalose Glucose 
molar ratio Size PI Size PI Size PI Size PI 
DPPC/DSPE-PEG1000 3:1 118 ± 4 0.094 ± 0.008 150 ± 10 0.273 ± 0.038 197 ± 16 0.447 ± 0.034 169 ± 16 0.357 ± 0.067 
5:1 110 ± 0 0.096 ± 0.001 138 ± 2 0.217 ± 0.004 198 ± 8 0.419 ± 0.024 156 ± 8 0.319 ± 0.045 
7:1 116 ± 1 0.073 ± 0.005 141 ± 10 0.222 ± 0.02 162 ± 5 0.307 ± 0.057 155 ± 11 0.297 ± 0.051 
DSPC/DSPE-PEG1000 3:1 116 ± 2 0.087 ± 0.007 173 ± 16 0.309 ± 0.033 276 ± 23 0.451 ± 0.018 269 ± 16 0.374 ± 0.029 
5:1 108 ± 5 0.086 ± 0.008 147 ± 5 0.257 ± 0.032 181 ± 8 0.326 ± 0.009 176 ± 8 0.326 ± 0.013 
DPPC/DSPE-PEG2000 3:1 103 ± 6 0.092 ± 0.01 170 ± 17 0.336 ± 0.041 152 ± 11 0.359 ± 0.031 259 ± 29 0.421 ± 0.051 
5:1 111 ± 6 0.069 ± 0.008 150 ± 5 0.247 ± 0.012 185 ± 22 0.367 ± 0.05 183 ± 3 0.326 ± 0.022 
Size and PI were determined by dynamic light scattering (Zetasizer).  Results shown are the mean ± S.E.M from at least three independent 





DPPC/DSPE-PEG1000 liposome (NT liposome) cryoprotected with sucrose at 
all 3 different sugar-to-lipid molar ratios (S/L ratio) showed minimal changes in 
vesicle size (< 20-30 nm) and acceptable narrow size distribution upon reconstitution 
0.222 to 0.279 (Table 5.1).  Change in size was not significantly different from the 
original size of the liposome before lyophilisation when cryoprotected with sucrose 
3:1 and 7:1 ratios (p > 0.05).  Although lyophilisation with sucrose 5:1 S/L ratio 
showed significant difference in size, the increase in size was minimal and 
consistently less than 24-26 nm.  However, for all other cryoprotectant ratios and 
sugars used, increase in size was significantly different (p < 0.05).  Since the use of  
higher amount of sugars (7:1) did not confer any additional benefit over the lower 
sugar concentrations, the other two CF-PEG liposomes were cryoprotected with 
sucrose, glucose and trehalose at 3:1 and 5:1 S/L ratio ratios only (excluding S/L ratio 
7:1).  
As shown in Table 5.1, DSPC/DSPE-PEG1000 liposomes were found to have 
minimal changes in size and PI when cryoprotected with sucrose at 5:1 S/L ratio.  
However, sucrose at 3:1 S/L ratio, glucose and trehalose at both the S/L ratio ratios 
showed substantial increase in size (> 50-150 nm) and PI (0.309 to 0.451).  Near 
doubling of size was noticed for trehalose or glucose when used at the lower 
concentration.  Similar results were obtained when DPPC/DSPE-PEG2000 liposomes 
were cryoprotected with glucose and trehalose at 3:1 and 5:1 S/L ratio.  It was 
observed that sucrose at both the S/L ratio did not confer any significant change in 
size (p > 0.05) and showed an acceptable narrow size distribution.  However, between 
the two ratios, S/L ratio of 5:1 showed minimal changes in both size and PI. Glucose 
at both ratios showed significant increase in size and PI (p < 0.05), whereas trehalose 




Though trehalose did not show any significant change in size when used in 5:1 S/L 
ratio, the PI was significantly higher than the PI of sucrose at 5:1 S/L ratio. 
Based on the observations, it can be concluded that sucrose at S/L ratio of 5:1 
showed most promising cryoprotectant effect on all different types of CF-PEG 
liposomes tested.  Therefore, this cryoprotectant and ratio was selected for further 
investigations.  This investigation was made on drug-free liposomes as drug loaded 
NT liposome showed significant carboplatin leakage upon lyophilisation and 
reconstitution (details in section 5.2.6). 
 
5.2.3 Effect of time of addition of cryoprotectant during liposome preparation  
Previous studies have shown that different process parameters can affect the 
lyophilisation process [225].  One such important aspect of lyophilisation is the time 
of addition of the cryoprotectant into the liposome.  If a cryoprotectant is added 
before the liposome bilayer formation (extrusion), it may remain inside the liposome 
vesicle.  Whereas, when a cryoprotectant added later, it remains on the outer side of 
the vesicle [221].  This presence of the cryoprotectants inside or outside the liposome 
vesicles has been previously shown to affect the relative stability of the membranes, 
thus influencing the sizes of the liposomes upon reconstitution [221].  Therefore, the 
effect of time of addition of cryoprotectant during liposome preparation was 
investigated by adding the cryoprotectant sucrose at S/L ratio 5:1 before extrusion and 
after extrusion.  As seen in the Figure 5.3, the time of addition of the cryoprotectants 
did not have any significant effect on the size and PI of the reconstituted lyophilised 
NT liposomes.  Since the exact lipid concentration in liposomes can only be 




cryoprotectant at the fixed S/L ratio was always performed after extrusion in all 
further studies.  
 
 
Figure 5.3:  Size (A) and PI (B) of DPPC/PEG1000 liposomes before (left bar) and 
after lyophilisation when the cryoprotectant was added either before extrusion (middle 
bar) or after extrusion (rightmost bar).  Results shown are the average values ± S.E.M 
obtained from at least three independent batches of formulation.  Some error bars are 




5.2.4 Size conformation by optical imaging of lyophilised and reconstituted NT 
liposomes 
The microscopic visualisation of freeze-dried product is a direct way to 
observe the microstructure of the freeze-dried matrix, and to observe whether any 
modification has occurred on their morphology.  FESEM studies were performed on 
the lyophilised powdered form of the liposomes to elucidate the effect of different 
cryoprotectants on the surface morphology of the lyophilised product.  Additionally, 
Cryo-FESEM images were taken to observe the nanostructure of the liposomes in 
reconstitution form.  This study also revealed the effect of different cryoprotectants on 
the size and shape of the reconstituted liposomes. 
 
 
Figure 5.4:  Field emission scanning electron microscopy (FESEM) images of 
lyophilised DPPC/PEG1000 liposomes in absence of cryoprotectant (A) or in presence 
of cryoprotectant sucrose (B), glucose (C) and trehalose (D).  All cryoprotectants 





The FESEM images (Figure 5.4) of the lyophilised NT liposomes showed 
intact liposome structures in the presence of different cryoprotectants; however, in the 
absence of any cryoprotectant, lyophilised liposomes were amorphous and much 
larger in size.  Higher magnification of non-cryoprotected lyophilised NT liposomes 
revealed absence of any intact liposome structures (Figure 5.4A).  On the other hand, 
closer observation of lyophilised liposome cryoprotected with sucrose the S/L ratio of 
5:1 showed the presence of liposomal structures of ׽100 nm in diameter (Figure 
5.4B).  Although, preservation of liposomal structures could be observed in 
lyophilised liposome cryoprotected with glucose or trehalose at S/L ratio of 5:1, size 
of such lyophilised liposomes was much bigger.  These liposomal structures (Figure 
5.4C, D) were found to be fused to one another, which may have resulted in bigger 
size and increased PI of the samples upon reconstitution. 
Similar inference can be drawn from Cryo-FESEM images of the lyophilised 
liposomes after reconstitution.  As seen in Figure 5.5 B, non-cryoprotected lyophilised 
liposomes showed manifold increase in size and PI after reconstitution.  In contrast, 
the presence of sucrose (S/L ratio of 5:1), did not show any significant change is size 
or PI of the lyophilised liposome after reconstitution when compared to non-
lyophilised liposomes (Figure 5.5C and 5.5D compared to 5.5A).  The size of 
reconstituted liposomes lyophilised with glucose (Figure 5.5E) or trehalose (Figure 
5.5F) at S/L ratio 5:1 was found to be slightly bigger than the non-lyophilised 
liposomes or lyophilised liposomes cryoprotected with sucrose.  These images 
confirmed the findings obtained by size analysis with Zetasizer.  Of note, all 
cryoprotected liposomes showed spherical shape and smooth surface morphology, 






Figure 5.5:  Cryogenic scanning electron microscopy (Cryo-FESEM) images of non-
lyophilised liposomes (A), lyophilised liposomes in absence of cryoprotectant (B) or 
in presence of cryoprotectant sucrose (C,D), glucose (E), and trehalose (F).  All 
lyophilised liposomes were reconstituted with milliQ water before optical imaging.  
Liposomes were composed of DPPC/PEG1000 and cryoprotectants were used at a 
sugar: lipid molar ratio of 5:1. Representative images have been shown. 
 
5.2.5 Moisture content determination by Karl Fischer titration 
Low moisture content is an essential criterion of any lyophilised product as 
this confers improved stability of the product by preventing any chemical reactions 




maximumal water content in freeze-dried products be within 3% (w/w) [226].  
Therefore, moisture content in the DPPC/DSPE-PEG1000 lyophilised liposomes was 
determined by Karl Fischer titration method.  The analysis revealed that the product 
had a low moisture (2.59 ± 0.18%) content post lyophilisation.  This entrapped 
moisture was within the allowable limit of 3% (w/w) and therefore indicated the 
suitability of the method.  Notably, the samples determined for moisture content were 
stored at 2-8°C for more than 2 months before analysis.  
 
5.2.6 Long-term stability of lyophilised liposomes  
As mentioned earlier, sucrose at S/L ratio of 5:1 was selected as the 
cryoprotectant of choice due to its favorable cryoprotective effects.  NT lyophilised 
liposomes demonstrated substantial stability on storage at 2-8°C as lyophilised 
product.  As seen in Figure 5.6A & 5.6B, no notable change in size and PI was 
observed when NT liposomes were stored as lyophilised product for 1 year.  In 
addition, no significant changes in size and PI were observed when NT lyophilised 
liposomes were reconstituted and stored as reconstituted liposomes for more than 2 
months (Figure 5.6C & 5.6D).  Therefore the lyophilised form of the liposomes was 




Figure 5.6:  Change in size (A, C) and polydispersity (B, D) of lyophilised 
DPPC/PEG1000 liposomes on storage at 2-8ºC in lyophilised form for a period of 1 
year (360 days) or after reconstitution and storage at 2-8ºC for a period of 60 days.  
Results shown are the mean ± S.E.M from at least three independent batches of 
formulation.  Some error bars are too small to be seen.  
 
5.2.7 Drug loading and drug release from reconstituted lyophilised NT liposomes  
One of the greatest challenge encountered in the lyophilisation of liposome is 
the prevention of drug leakage after reconstituion.  This becomes extremely 
uncontrollable when the encapsulated drug is itself hydrophilic because the 
withdrawal of water from the liposomal core would result in the leakage of 
encapsulated drug out of the vesicle.  Although, presence of cryoprotectant could 
restore the original size of the NT liposomes after lyophilisation and reconsitituion, 
significant drug leakage was observed in the drug loaded samples.  As expected and 
observed in Figure 5.7, carboplatin content in drug loaded NT liposomes decreased by 




alternative method was employed to have a lyophilised liposome product drug loaded 
with carboplatin.  As mentioned in chapter 2, section 2.2.3, carboplatin loading is 
executed in preformed liposomes by passive equilibration method.  Therefore, 
carboplatin loading was carried out with lyophilised liposomes after reconsitution, as 
and when required.  
Figure 5.7 shows that when carboplatin was loaded into the reconstituted 
lyophilised NT liposomes, it exhibited significantly higher drug loading than the non-
lyophilised liposomes (p < 0.05). D/L ratio of drug-loaded, reconstituted lyophilised 
NT liposomes was 0.083 ± 0.001 (w/w), almost 80% more than carboplatin loaded 
into non-lyophilised NT liposomes.  It was investigated whether the presence of 
sucrose in the liposomes core was responsible for the enhanced drug loading capacity 
of the lyophilsed liposomes.  Therefore, carboplatin loading was performed with NT 
liposome (non-lyophilised) which had sucrose added to them previously at S/L ratio 
molar ratio of 5:1.  However, data obtained showed that these liposomes exhibited 
significantly lower D/L of 0.030 ± 0.002 (w/w), when compared to the NT liposomes 






Figure 5.7:  Final carboplatin-to-lipid weight ratios of DPPC/PEG1000 liposomes on 
loading before lyophilisation (1), after reconstitution of lyophilised liposomes (2), 
upon carboplatin loading into reconstituted lyophilised liposomes (3) or carboplatin 
loading into DPPC/PEG1000 liposomes with sucrose externally added (4) at sugar: 
lipid molar ratio of 5:1. Results shown are the mean ± S.E.M from at least three 
independent batches of formulation.   
 
Figure 5.8 illustrates the release profiles of carboplatin from lyophilised NT 
liposomes and non-lyophilised NT liposomes following dialysis against 1000-fold 
excess phosphate buffered saline at 37°C. In general, both the lyophilised and non-
lyophilised liposomes exhibited an initial rapid release of carboplatin where 20% of 
the drug was released within the first 8 h.  Subsequently, 15-30% of drug was released 
within the next 64 h. At 72 h, percentage of drug remaining in lyophilised and non-
lyophilised liposomes was about 65% and 50%, respectively.  Notably the difference 
in release profile for lyophilised and non-lyophilised liposomes were not statistically 
significant though the D/L in lyophilised liposome was higher than the non-






Figure 5.8:  Cumulative release of carboplatin from lyophilised (■) or non-lyophilised 
(♦) NT liposomes.  Results shown are the mean ± S.E.M from at least three 
independent batches of formulation.  Some error bars are too small to be seen.  
 
Carboplatin loading was also performed into another CF-PEG liposomes 
(DSPC/DSPE-PEG1000) to investigae the effect of lyophilisation on the loading 
capacity of other liposomes.  In contrary to the expectation, drug loading in 
lyophilised and reconsituted  DSPC/DSPE-PEG1000 liposomes did not confer any 
statistically significant improvement when compared to its non-lyophilised 
counterpart.  As observed in Figure 5.9, D/L in lyophilised DSPC/DSPE-PEG1000 
liposomes was 0.040 ± 0.003 (w/w) whereas in non-lyophilised liposomes was 0.031 






Figure 5.9: Final carboplatin-to-lipid weight ratios of DSPC/DSPE-PEG1000 liposomes 
on loading before lyophilisation (1), and carboplatin loading into reconstituted 
lyophilised liposomes (2). Results shown are the mean ± S.E.M from at least three 
independent batches of formulation.   
 
5.2.8 Effect of cryoprotection on the phase transition temperature of lyophilised 
NT liposomes 
Lyophilised liposomes are included within a vitrified matrix of cryoprotectant 
and are stored at a temperature below the temperature of phase transition temperature 
(Tm) of the dried formulation to prevent any shrinkage of the freeze-dried cake.  By 
adding disaccharides such as trehalose or sucrose, Tm (also known as the gel to liquid 
transition temperature) of the lipids is lowered by the direct interaction of the 
hydroxyl groups of the disaccharides and the polar head groups of the lipids by 
hydrogen bonding [225].  This temperature of gel to liquid phase transition may be 
determined by differential scanning calorimetry.  Differential scanning calorimetry 
(DSC) is very useful to study the interaction between the cryoprotectants and the 
liposomes with and without the cryoprotectant.  Here the Tm of the liposomes 
lyophilised with different cryoprotectants was determined.   
As observed in Figure 5.10, all lyophilised NT liposomes had a smooth phase 




43°C.  It is noteworthy that the Tm value of all lyophilised liposomes was near to the 
Tm value of  pure DPPC (41.1 °C) [221].  As expected, addition of cryoprotectant 
lowered the Tm of the liposomes when compared with non-lyophilised liposomes and 
lyophilised liposomes without cryoprotectant.  However, sucrose at S/L ratio 5:1 
among the three sugars significantly depressed the Tm of the lyophilised liposomes (p 
< 0.05).  As seen in Table 5.2, this depression of Tm with addition of sucrose was also 
significantly different when compared to non-lyophilised liposome and lyophilised 
liposomes without cryoprotectants (p < 0.05).  However, glucose and trehalose did 
not confer a significant influence on the Tm of the non-lyophilised liposome and 
lyophilised liposomes without cryoprotectants (p > 0.05).  
 
 
Figure 5.10:  DSC curves of non-lyophilised liposomes (A), lyophilised liposomes 
without cryoprotectant (B), lyophilised liposomes in presence of cryoprotectant 
sucrose (C), glucose (D), and trehalose (E).  Values corresponding to the curves 
indicate representative Tm values.  NT liposomes were cryoprotected at a sugar: lipid 
molar ratio of 5:1.  All lyophilised liposomes were reconstituted in water before the 
measurement.  All scans were done in duplicates and at least three different batches of 






Table 5.2: Effect of different cryoprotectants on the phase transition temperature (Tm) 
of liposomes  
 
Samples Tm 
Non lyophilised liposomes 43.06 ± 0.05 
Lyophilised liposomes without cryoprotectants 42.94 ± 0.03 
Lyophilised with Sucrose 5:1 42.58 ± 0.01a 
Lyophilised with Glucose 5:1 42.88 ± 0.02 
Lyophilised with Trehalose 5:1 42.96 ± 0.08 
Tm values were determined from the DSC curves of the liposomes.  All scans were 
done in duplicates and at least three different batches of liposome formulations were 
evaluated.  a p < 0.05 for liposomes lyophilised with sucrose 5:1 vs. all other groups. 
 
5.2.9 Effect of cryoprotectants on lyophilisation of FRT liposomes 
 Upon investigation of the effective cryoprotection of the NT liposomes and 
subsequent drug loading, FRT liposomes were also lyophilised with different types of 
cryoprotectants with the aim to prolong their storage shelf life.  Similar to NT 
liposomes, lyophilisation without cryoprotectant did not confer any advantage as both 
sizes and PI of the FRT liposomes increased tremendously.  Initial studies showed 
that sugars at S/L ratio 3:1 also could not restore the original size of the liposomes and 
both size and PI increased considerably (n = 1).  Therefore, sucrose, glucose and 
trehalose at S/L ratio 5:1 and 7:1 were investigated for effective cryoprotection of 
FRT liposomes.  Results obtained were similar to NT liposomes, were sucrose at S/L 
ratio 5:1 showed minimal changes in size and PI upon lyophilisation and 
reconstitution (Table 5.3).  Altogether, not all the three sugars at both S/L ratio ratios 
conferred any significant changes on the size and PI of the liposome before and after 
lyophilisation.  However, more than two fold changes in PI were observed in 




distribution of lyophilised liposomes also increased considerably when cryoprotected 
with sucrose at S/L ratio 7:1.  Taken together, sucrose at S/L ratio of 5:1 was selected 
for cryoprotection of FRT liposomes for subsequent studies.  Samples stored at 2-8°C 
as lyophilised product for a period of 2 months did not show any significant deviation 
in size and PI, indicating suitability of the cryoprotectant for long-term storage.  The 
long-term stability of  lyophilised FRT liposomes has been proposed as future study. 
 
Table 5.3: Size and polydispersity index (PI) of FRT liposomes before or after 
lyophilisation in the presence of different cryoprotectants 
 
Cryoprotectant  Before Lyophilisation After Lyophilisation 
Type & Ratio Size PI Size PI 
Sucrose 5:1 116 ± 4 0.125 ± 0.005 140 ± 10 0.202 ± 0.011 
Sucrose7:1 115 ± 3 0.119 ± 0.008 145 ± 16 0.296 ± 0.061 
Trehalose 5:1 111 ± 6 0.135 ± 0.006 248 ± 64 0.369 ± 0.081 
Trehalose 7:1 115 ± 3 0.119 ± 0.008 193 ± 17 0.384 ± 0.036 
Glucose 5:1 108 ± 5 0.120 ± 0.008 171 ± 25 0.270 ± 0.029 
Glucose 7:1 115 ± 3 0.119 ± 0.008 157 ± 20 0.312 ± 0.043 
Size and PI were determined by dynamic light scattering (Zetasizer).  Results shown 
are the mean ± S.E.M from at least three independent batches of formulation 
 
5.2.10 Drug loading into reconstituted lyophilised FRT liposomes 
Unlike NT lyophilised liposomes, carboplatin loading in lyophilised and 
reconstituted FRT liposomes did not confer any advantage.  However, the final D/L 
ratio of the lyophilised FRT liposome and non-lyophilised liposomes were similar, 
without any significant difference (p > 0.05).  As observed in Figure 5.11, the final 
D/L ratios achieved in the non-lyophilised FRT liposome and the lyophilised-FRT 
liposomes were 0.054 ± 0.006 (w/w) and 0.047 ± 0.004 (w/w), respectively.  Of note, 
lyophilisation and subsequent drug loading did not alter the cytotoxic properties and 





Figure 5.11:  Final carboplatin-to-lipid weight ratios of FRT liposomes on loading 
before lyophilisation (1), and carboplatin loading into reconstituted lyophilised 
liposomes (2).  Results shown are the mean ± S.E.M from at least three independent 
batches of formulation.   
 
5.3. Discussion  
The major objective of this chapter was to identify methods to prolong the 
long-term stabilities of the NT and FRT liposomes.  Additionally, this chapter also 
attempted to characterise the lyophilisation of cholesterol free PEGylated liposomes.  
These CF-PEG liposomes have been shown to be potential carriers for anticancer 
drugs in vivo [181, 227].  Additionally, both the NT and FRT liposomes developed 
could be categorised as CF-PEG liposomes.  In this study, the effects of lyophilisation 
on the size, long-term stability, hydrophilic drug loading and drug release properties, 
and the impact of cryoprotectants on the Tm of CF-PEG liposomes were evaluated.  
Several important observations were made which are discussed as follows.   
The study found that lyophilisation in the presence of cryoprotectant 
minimised changes in liposome sizes and PI.  Sucrose at S/L ratio 5:1 was found to be 
superior to trehalose and glucose as a cryoprotectant for all CF-PEG liposome 




containing liposomal systems have been reported using maltose  and trehalose as 
cryoprotectants [228, 229].  In general, an increase in S/L ratio corresponds to a better 
cryoprotective effect of the disaccharides.  However, for all three sugars tested, best 
results were obtained with the S/L ratio ratio of 5:1.  Increase in cryoprotectant 
concentration may have led to a more concentrated system that could not restore its 
original size upon reconstitution.  Previous studies done on the optimal cryoprotective 
amount of trehalose and sucrose on soy phosphatidylcholine and maltotriose on DPPC 
liposomes have shown a similar trend where exceedingly high or low concentrations 
of sugars diminished the cryoprotective capability [222, 230].  Overall, the 
disaccharides (sucrose or trehalose) exhibited better cryoprotective capability than 
monosaccharide (glucose) for the different CF-PEG liposomal systems investigated. 
The protective effect of sucrose at S/L ratio 5:1 during lyophilisation and 
reconstitution could be associated to the decreased Tm of the liposome bilayer.  
Previous reports on glucose as cryoprotectant have indicated its effectiveness in 
reducing Tm of the phospholipid in dry state [231].  Ohtake et al. have also suggested 
the role of trehalose in decreasing the Tm of DPPC and DPPC-cholesterol liposomes 
when present on the outer and inner sides of the phospholipids membranes [232, 233].  
This effect could be seen in DSC studies when significant decrease of Tm was 
achieved after addition of sucrose into the lyophilised liposome system.  
All the different CF-PEG and FRT liposomes cryoprotected with sucrose at 
S/L ratio of 5:1 showed minimal changes in size and PI upon storage for one-year at 
2-8°C as a lyophilised product.  Additionally, the reconstituted liposomes also did not 
show any significant change is size of PI upon storage for 2 months.  This indicated 
that presence of sucrose at this ratio did not promote vesicle fusion upon storage even 




When lyophilisation of carboplatin-loaded liposomes was performed, it 
showed significant drug leakage even in presence of cryoprotectant.  This was 
expected as carboplatin is a hydrophilic drug [234].  Studies reported on 
lyophilisation of other hydrophilic drugs encapsulated liposome systems yielded 
similar results [229, 235].  However, in these studies the percentage of drug leakage is 
reportedly lower compared to the present study.  This is possibly due to the presence 
of cholesterol in liposome bilayer structure and the inherent chemical nature of the 
encapsulated hydrophilic drugs [229, 235].  However, when carboplatin was loaded 
after lyophilisation and reconstitution into NT and FRT liposomes after lyophilised 
with sucrose as cryoprotectant, promising D/L ratio could be achieved.  Most 
strikingly, carboplatin loading in reconstituted NT liposomes was much higher than 
that of non-lyophilised NT liposomes, whereas FRT liposomes showed similar 
loading efficiencies.  This increased loading could be due to possible interactions 
between sucrose and carboplatin moiety within the liposomal aqueous core.  
Carboxylic groups of carboplatin may have formed hydrogen bonding with the 
hydroxyl groups of sucrose thereby stabilising the drug loaded liposomal core.  
Previous reports have indicated the role of hydrogen bonding on better drug retention 
after lyophilisation of liposomes [236, 237].  Furthermore, when sucrose was added 
externally to the NT liposomes it could not improve the D/L ratio suggesting that 
sucrose did not facilitate the entry of carboplatin but rather presence of sucrose inside 
the vesicles caused the higher loading efficiencies.  However, such enhanced 
carboplatin loading could not be observed in DSPC/DSPE-PEG1000 liposomes and 
FRT liposomes suggesting that drug loading after reconstitution may be further 
influenced by the composition of the lipid bilayer.  This have been previously 




influences not only drug retention but also size and PI during freeze-drying and after 
reconstitution [238].   
To investigate whether lyophilised liposomes loaded with carboplatin are able 
to provide a sustained drug release similar to its non-lyophilised counterpart, in vitro 
drug release assay was performed.  Release of carboplatin from non-lyophilised and 
lyophilised cryoprotected liposomes appeared similar and showed a sustained release 
pattern as that of other liposomal drug formulations [235].  The result obtained 
indicates that lyophilisation did not impart any negative impact on the drug release 
properties of the liposomes.  In addition, though NT lyophilised liposomes had higher 
drug loading than the non-lyophilised counterpart, it did not show an accelerated drug 
release pattern but had a similar release trend.  
 
5.4. Conclusion 
Overall, the results indicate that lyophilisation with sucrose at sugar-to-lipid ratio 
of 5:1 was suitable for long-term storage of both NT and FRT liposomes.  
Furthermore, lyophilisation was advantageous as the reconstituted lyophilised NT 
liposomes exhibited superior drug loading compared to its non-lyophilised 
counterpart whereas the reconstituted lyophilised FRT liposomes also showed similar 
drug loading property without affecting its drug release pattern.  The results could 
also provide valuable insights for future studies on lyophilisation of cholesterol free 






CONCLUSION AND FUTURE DIRECTIONS 
 
6.1. Conclusion 
The aim of this project was to develop a FR targeted formulation of the 
platinum drug carboplatin for the treatment of FR positive ovarian cancer.  To achieve 
the above goal, a stepwise approach was adopted. First, the folate receptor targeted 
(FRT) and non-targeted (NT) liposome formulations of carboplatin were developed 
and optimised (chapter 3).  The results showed that both FRT and NT liposomes had 
similar drug loading with  final drug-to-lipid ratios of 0.057 ± 0.006 and 0.062 ± 
0.004 respectively. FRT liposomes also exhibited similar in vitro drug release profile 
when compared to that of NT liposomes.  From a formulation perspective, this was 
noteworthy as the final D/L weight ratios of NT and FRT liposomes were found to be 
higher than those of cisplatin liposomal formulation SPI-077 and cisplatin 
thermosensitive liposomes. 
In chapter 3, we also investigated the in vitro efficacy of our formulation on 
FR positive and negative cell line.  The results obtained showed that FRT liposomes 
had significantly higher cytotoxicity than NT liposomes and free drug when tested on 
FR positive KB cells.  These results are in agreement with other FR targeted 
formulations of doxorubicin, 5-FU, paclitaxel and docetaxel [5-8].  As expected, the 
IC50 values of the formulations and free drug were not significantly different when 
tested on FR negative A549 cells.  These results were further corroborated by cellular 




in FR positive cells, whereas no difference was observed in FR negative cells.  
Cellular uptake of fluorescent dye loaded liposomes showed effective internalisation 
of the FRT system in both KB cells.  However, when DNA-Pt adduct formation was 
assessed in KB cells it did not show any significant difference from free drug.  This 
probed the investigation of other possible mechanism behind the enhanced 
cytotoxicity of the FRT liposomes.  Western blot studies showed activation of ERK in 
presence of both carboplatin-loaded and nonleaded liposomes.  This activation of 
ERK was concentration dependent and could be reversed in presence of ERK 
inhibitors. MTT assay in presence of ERK inhibitors confirmed this finding.  Overall, 
it could be suggested that the improved therapeutic efficacy of carboplatin loaded 
FRT liposomes could be attributed to the effective internalisation of the FRT 
liposomes into the FR over expressing cells and by activation of the ERK pathway.  
The next aim of the thesis was to test the hypothesis in the in vivo human 
ovarian cancer xenograft model (chapter 4).  For this, the FRT formulation was 
initially evaluated for its in vitro cytotoxicity in IGROV1 cells.  Results obtained from 
cytotoxicity studies, cellular uptake of fluorescent liposomes, and cellular Pt-uptake 
were similar to results obtained in KB cells.  For the in vivo studies, an FR positive 
ovarian cancer xenograft model was established in SCID mice by intra peritoneal (i.p) 
injection of IGROV1 cells.  It was observed that localised treatment of ovarian cancer 
by i.p injection of FRT liposomes significantly increased the survival time of the 
mice.  Five-out-of-six FRT liposome treated mice were long-term survivors with a 
survival rate of 83%.  Whereas, all other groups such as saline control, free drug and 
NT liposome died within 20-30 days of tumour cell inoculation.  These findings are of 
crucial importance as they highlighted the improved efficacy of carboplatin upon 




toxicity through H & E staining showed that FRT liposomes did not impart any 
significant toxicity on the animals.  Thus, the carboplatin loaded FRT liposomal 
formulation could be a promising therapy for the treatment of FR positive ovarian 
cancer.   
However, though the formulation was effective in enhancing the therapeutic 
efficacy of the drug, one major obstacle faced during this project was the long-term 
stability.  It was found that both NT and FRT liposome formulations had significant 
drug loss during storage at 2-8ºC for one year.  This drug leakage from liposomes 
could be attributed to the absence of cholesterol in formulation composition.  To 
circumvent this problem, lyophilsation of liposomes was investigated in chapter 5.  It 
was also interesting to investigate this aspect as lyophilisation of cholesterol free 
PEGylated liposomes has not been extensively investigated before.  Therefore, the 
effects of different cryoprotectants on lyophilised liposome size, polydispersity index, 
long-term stability, phase transition temperature, drug loading capacity and drug 
release pattern were investigated.  The results showed that sucrose as a cryoprotectant 
(sugar-to-lipid ratio of 5:1) could protect liposome size and structure on reconstitution 
and was superior to glucose and trehalose for all types of liposomal compositions.  
Size and polydispersity index determination by Zetasizer and visual observations by 
FESEM and Cryo-SEM studies confirmed our findings.  This lyophilised product 
showed considerable stability for one-year storage as a freeze-dried product.  Most 
importantly, lyophilisation of liposomes with sucrose as cryoprotectant was highly 
advantageous as it could significantly enhance the carboplatin loading into 
reconstituted NT liposomes.  This observation was particularly interesting as this may 
result in the development of a formulation kit of carboplatin-liposomes, which could 




recommended which will highlight the practicability of using this formulation kit in 
real clinical settings.  
Overall, this thesis was successful in developing a FRT liposomal formulation 
of carboplatin.  The formulation demonstrated superior efficacy and reduced toxicity 
than the free drug and non-targeted liposomes in both in vitro and in vivo ovarian 
cancer model.  The results may also help to develop other NT and FRT lyophilised 
liposome products encapsulating different hydrophilic drugs.  
 
6.2. Future directions 
Though the formulation showed promising therapeutic efficacy, further 
evaluation is compulsory to be acceptable for use in real clinical settings.  Therefore, 
a number of future studies could be proposed which can be broadly classified under 
the following headings.  
 
6.2.1 Formulation perspective 
One limitation of the study was the failure to assess the effects of other storage 
variables upon long-term storage of lyophilised liposomes due to selection of a single 
storage condition [193].  Studies carried out on lyophilised liposome systems have 
shown that lyophilised liposomes stored at different temperatures over long periods 
resulted in varying liposomal sizes upon reconstitution even when cryoprotected with 
suitable types and amounts of cryoprotectant [239].  Storage below the glass transition 
temperature (Tg) of the sugar matrix has been reported to be essential as temperatures 
above the Tg of the sugar causes a decrease in viscosity leading to physical changes 
such as stickiness, shrinkage and collapse of lyophilised cake, crystallisation of buffer 




both the reconstituted liposomes and freeze-dried products were performed below the 
Tg of sucrose (65°C), trehalose (110°C) and glucose (30°C), it may have prevented 
the fusion of the vesicles [241].  In addition, relative humidity also plays an important 
part in storage of lyophilised cakes cryoprotected with sugars as high relative 
humidity would lead to adsorption of moisture by lyophilised cakes leading to a 
depression of Tg below that of storage temperatures [238, 242].  Hence, future 
stability tests could involve running an accelerated stability studies over different 
temperature and relative humidity conditions  to assess the long term stability of this 
lyophilised product [243].  
Another challenge for the development of the formulation kit for lyophilised 
FRT liposome is the separation of the un-encapsulated drug.  Currently un-
encapsulated carboplatin was separated using Sephadex G-50 by centrifugation.  
However, such instrumentations may not be available in real clinical settings.  
Therefore a one-step drug loading and separation method should be developed which 
can be performed with minimal equipments as found in hospitals and clinics.  This 
may lead to the development of a formulation kit supplied containing lyophilised FRT 
powder, sterile water for reconstitution and carboplatin in one package.  
 
6.2.2 Clinical perspective 
Since the formulation was advantageous in increasing the survival time of the 
mice, long-term survival studies of 120 days or more could be done on this model to 
estimate the median survival time of mice on treatment with carboplatin loaded FRT 
liposomes.  Maximum tolerated dose of the FRT liposomes could be determined since 




excised tissues of mice.  Additional toxicity studies could be done with dose 
escalation to determine the optimal dose to be used from preclinical studies.   
The FRT liposomes could be further evaluated on other in vivo FR positive 
ovarian cancer models.  Additionally the potential of this FRT formulation in treating 
other FR positive cancer may open new avenues for the treatment of cervical cancer, 
uterine cancer, bladder cancer, renal cancer.  Therefore, in vitro and in vivo studies 
could be performed on these cancer cell lines and models, if available.  In vitro 
evaluation of the formulation could also be performed on clinically available patient 
samples before testing on human subjects.  Promising results from pre-clinical studies 
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